Andrew John Armstrong | Scholars@Duke

Andrew John Armstrong
Professor of Medicine

1. Predictors of sensitivity and clinical efficacy of therapies in advanced prostate cancer
2. Novel designs of clinical trials and pharmacodynamic/translational studies in prostate, kidney, bladder cancer
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, bladder, and testicular cancer
5. Design of rational combination therapies in men with metastatic hormone-refractory prostate cancer
6. PI3 kinase/mTOR inhibition in prostate cancer: mechanisms of sensitivity and resistance
7. Developing prognostic models for progression and survival in metastatic prostate cancer
8. Examining surrogate markers of mortality in metastatic prostate cancer
9. Clear cell and non-clear cell renal cell carcinoma: natural history, sensitivity to novel agents including mTOR and VEGF inhibition

Office Hours

Tuesdays, Wednesdays and Fridays. Contact Peggy Cook, my assistant at peggy.cook@dm.duke.edu for appointments. Or 919-668-4667.

Current Appointments & Affiliations

Professor of Medicine, Medicine, Medical Oncology, Medicine 2018
Professor in Surgery, Surgery, Urology, Surgery 2018
Professor in Pharmacology and Cancer Biology, Pharmacology & Cancer Biology, Basic Science Departments 2021
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2006

Contact Information

Duke Box 103861, Durham, NC 27710
GSRB1 Room 3006, 905 La Salle St, Durham, NC 27710
andrew.armstrong@duke.edu (919) 668-8797

Background
Education, Training, & Certifications
- M.Sc., Johns Hopkins University 2008
- Fellowship, Division Of Oncology/Hematology, Johns Hopkins University School of Medicine 2003 - 2006
- Internship/Residency, General Internal Medicine, University of Pennsylvania, School of Medicine 2000 - 2003
- M.D., University of Virginia School of Medicine 2000
- B.S.E., Duke University 1996
Previous Appointments & Affiliations
- Associate Professor in Pharmacology and Cancer Biology, Pharmacology & Cancer Biology, Basic Science Departments 2015 - 2021
- Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2014 - 2018
- Associate Professor in Surgery, Surgery, Urology, Surgery 2017 - 2018
- Associate Professor in Surgery, Surgery, Vascular and Endovascular Surgery, Surgery 2012 - 2017
- Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2012 - 2014
- Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 2006 - 2011
- Assistant Professor in Surgery, Surgery, Urology, Surgery 2007 - 2011
Recognition
In the News
- MAR 7, 2023 School of Medicine
  
  A New Avenue for Prostate Cancer Treatment
- MAY 12, 2021 Duke Health News
  
  Study Confirms Racial Differences in Response to Prostate Cancer Treatment
- MAY 28, 2019 Duke Health News
  
  Study Finds How Prostate Cancer Cells Mimic Bone When They Metastasize
- JUN 5, 2018 Duke Health News
  
  Tests Identify Who Would Benefit from Advanced Prostate Cancer Therapies
- MAY 26, 2018 Duke Health News
  
  Bone Scan Software Accurately Calculates Prognosis for Advanced Prostate Cancer
- NOV 9, 2015 WRAL
  
  Moustaches fundraise for cancer in 'Movember' movement
- MAY 18, 2015 Duke Today
  
  Duke-led study clarifies best treatments for uncommon kidney cancers
- NOV 19, 2013 Duke Today
  
  Oral Drug May Improve Survival in Men with Metastatic Prostate Cancer
Expertise
Global Scholarship
- Research
- Teaching
  - China (Country)
Research
Selected Grants
External Relationships
- Astellas Pharma Inc.
- AstraZeneca
- Bayer
- Bill Albrecht
- Bristol-Myers Squibb
- Clearview Health Partners
- Clinical Advances in Hematology Oncology
- Epic Sciences
- Expert Connect
- Global Guidepoint
- GoodRx
- Ideaya Biosciences
- Janssen Pharmaceuticals (Johnson & Johnson)
- MJH Life Sciences
- Merck Sharpe & Dohme (Merck & Co, USA)
- Myovant Sciences, Inc
- Neil Love CME
- OncLive
- Pfizer Inc.
- WebMD/Medscape
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Halabi, Susan, Qian Yang, Akash Roy, Bin Luo, John C. Araujo, Christopher Logothetis, Cora N. Sternberg, et al. “External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.” J Clin Oncol 41, no. 15 (May 20, 2023): 2736–46. https://doi.org/10.1200/JCO.22.02661.
    Full Text Link to Item
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer.” Clin Cancer Res 29, no. 10 (May 15, 2023): 1929–37. https://doi.org/10.1158/1078-0432.CCR-22-3233.
    Full Text Link to Item
  - Wang, Mu-En, Jiaqi Chen, Yi Lu, Alyssa R. Bawcom, Jinjin Wu, Jianhong Ou, John M. Asara, et al. “RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F/ACSL4 axis.” J Clin Invest 133, no. 10 (May 15, 2023). https://doi.org/10.1172/JCI166647.
    Full Text Open Access Copy Link to Item
  - Armstrong, Andrew J., Taro Iguchi, Arun A. Azad, Arnauld Villers, Boris Alekseev, Daniel P. Petrylak, Russell Z. Szmulewitz, et al. “The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES.” Eur Urol, May 11, 2023. https://doi.org/10.1016/j.eururo.2023.04.002.
    Full Text Link to Item
  - Brown, Landon C., and Andrew J. Armstrong. “Germline Testing in Prostate Cancer: Implementation and Disparities of Care.” Jco Oncol Pract 19, no. 5 (May 2023): 221–23. https://doi.org/10.1200/OP.22.00804.
    Full Text Link to Item
  - Butler, William, Lingfan Xu, Yinglu Zhou, Qing Cheng, J Spencer Hauck, Yiping He, Robert Marek, et al. “Oncofetal protein glypican-3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancer.” J Pathol 260, no. 1 (May 2023): 43–55. https://doi.org/10.1002/path.6063.
    Full Text Link to Item
  - Gillessen, Silke, Alberto Bossi, Ian D. Davis, Johann de Bono, Karim Fizazi, Nicholas D. James, Nicolas Mottet, et al. “Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.” Eur J Cancer 185 (May 2023): 178–215. https://doi.org/10.1016/j.ejca.2023.02.018.
    Full Text Link to Item
  - Morris, Michael J., Glenn Heller, David W. Hillman, Olivia Bobek, Charles Ryan, Emmanuel S. Antonarakis, Alan H. Bryce, et al. “Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial).” J Clin Oncol, March 30, 2023, JCO2202394. https://doi.org/10.1200/JCO.22.02394.
    Full Text Link to Item
  - McManus, Hannah D., and Andrew J. Armstrong. “The Past, Present, and Future of Treatment Intensification for Metastatic Hormone-Sensitive Prostate Cancer.” J Clin Oncol, March 22, 2023, JCO2300323. https://doi.org/10.1200/JCO.23.00323.
    Full Text Link to Item
  - Gillessen, Silke, Alberto Bossi, Ian D. Davis, Johann de Bono, Karim Fizazi, Nicholas D. James, Nicolas Mottet, et al. “Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.” Eur Urol 83, no. 3 (March 2023): 267–93. https://doi.org/10.1016/j.eururo.2022.11.002.
    Full Text Link to Item
  - Wang, Edina C., W Robert Lee, and Andrew J. Armstrong. “Second generation anti-androgens and androgen deprivation therapy with radiation therapy in the definitive management of high-risk prostate cancer.” Prostate Cancer Prostatic Dis 26, no. 1 (March 2023): 30–40. https://doi.org/10.1038/s41391-022-00598-3.
    Full Text Link to Item
  - Butler, William, Colin McDowell, Qing Yang, Yiping He, Yue Zhao, J Spencer Hauck, Yinglu Zhou, et al. “Rewiring of the N-Glycome with prostate cancer progression and therapy resistance.” Npj Precis Oncol 7, no. 1 (February 24, 2023): 22. https://doi.org/10.1038/s41698-023-00363-2.
    Full Text Link to Item
  - Hawkey, Nathan M., Amanda Broderick, Daniel J. George, Oliver Sartor, and Andrew J. Armstrong. “The Value of Phenotypic Precision Medicine in Prostate Cancer.” Oncologist 28, no. 2 (February 8, 2023): 93–104. https://doi.org/10.1093/oncolo/oyac198.
    Full Text Link to Item
  - Broderick, Amanda, Matthew K. Labriola, Neal Shore, and Andrew J. Armstrong. “Foreign accent syndrome as a heralding manifestation of transformation to small cell neuroendocrine prostate cancer.” Bmj Case Rep 16, no. 1 (January 30, 2023). https://doi.org/10.1136/bcr-2022-251655.
    Full Text Link to Item
  - Gratzke, Christian, Mariusz Kwiatkowski, Ugo De Giorgi, Karine Martins da Trindade, Maria De Santis, Andrew J. Armstrong, Cuizhen Niu, Yingjie Liu, and Christian Heinrich Poehlein. “KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer.” Future Oncol, January 27, 2023. https://doi.org/10.2217/fon-2022-0776.
    Full Text Link to Item
  - Berger, Benjamin T., Matthew K. Labriola, Emmanuel S. Antonarakis, and Andrew J. Armstrong. “Response to bipolar androgen therapy and PD-1 inhibition in a patient with metastatic castration-resistant prostate cancer and a germline CHEK2 mutation.” Bmj Case Rep 16, no. 1 (January 18, 2023). https://doi.org/10.1136/bcr-2022-251320.
    Full Text Link to Item
  - Green, Michelle F., Catherine H. Watson, Sarah Tait, Jie He, Dean C. Pavlick, Garrett Frampton, Jinny Riedel, et al. “Concordance Between Genomic Alterations Detected by Tumor and Germline Sequencing: Results from a Tertiary Care Academic Center Molecular Tumor Board.” Oncologist 28, no. 1 (January 18, 2023): 33–39. https://doi.org/10.1093/oncolo/oyac164.
    Full Text Open Access Copy Link to Item
  - Coombes, R. C., P. D. Badman, J. P. Lozano-Kuehne, X. Liu, I. R. Macpherson, I. Zubairi, R. D. Baird, et al. “Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer.” Nat Commun 14, no. 1 (January 17, 2023): 260. https://doi.org/10.1038/s41467-023-35969-4.
    Full Text Link to Item
  - Fizazi, K., P Gonzalez Mella, D. Castellano, J. N. Minatta, A. R. Kalebasty, D. Shaffer, JC Vazquez Limon, et al. “Nivolumab Plus Docetaxel in Patients With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Results From the Phase II Checkmate 9KD Trial.” Journal of Urology 209, no. 2 (2023): 445–46.
    Link to Item
  - Jindal, Rashi, Abheepsa Nanda, Maalavika Pillai, Kathryn E. Ware, Divyoj Singh, Manas Sehgal, Andrew J. Armstrong, Jason A. Somarelli, and Mohit Kumar Jolly. “Emergent dynamics of underlying regulatory network links EMT and androgen receptor-dependent resistance in prostate cancer.” Comput Struct Biotechnol J 21 (2023): 1498–1509. https://doi.org/10.1016/j.csbj.2023.01.031.
    Full Text Link to Item
  - Ware, Kathryn E., Beatrice C. Thomas, Pelumi D. Olawuni, Maya U. Sheth, Nathan Hawkey, M. Yeshwanth, Brian C. Miller, et al. “A synthetic lethal screen for Snail-induced enzalutamide resistance identifies JAK/STAT signaling as a therapeutic vulnerability in prostate cancer.” Front Mol Biosci 10 (2023): 1104505. https://doi.org/10.3389/fmolb.2023.1104505.
    Full Text Link to Item
  - Armstrong, Andrew J., Brad Rosbrook, Shunsuke Yamada, and Shunsuke ARCHES authors. “Reply to R. Sun et al.” J Clin Oncol 40, no. 36 (December 20, 2022): 4279–80. https://doi.org/10.1200/JCO.22.01470.
    Full Text Link to Item
  - Dzimitrowicz, Hannah E., and Andrew J. Armstrong. “Triplet Therapy: Entering the Metaverse of Metastatic Hormone-sensitive Prostate Cancer Treatment.” Eur Urol 82, no. 6 (December 2022): 599–601. https://doi.org/10.1016/j.eururo.2022.08.031.
    Full Text Link to Item
  - Kotamarti, Srinath, Andrew J. Armstrong, Thomas J. Polascik, and Judd W. Moul. “Molecular Mechanisms of Castrate-Resistant Prostate Cancer.” Urol Clin North Am 49, no. 4 (November 2022): 615–26. https://doi.org/10.1016/j.ucl.2022.07.005.
    Full Text Link to Item
  - Zhao, Shuang G., Jamie M. Sperger, Jennifer L. Schehr, Rana R. McKay, Hamid Emamekhoo, Anupama Singh, Zachery D. Schultz, et al. “A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer.” J Clin Invest 132, no. 21 (November 1, 2022). https://doi.org/10.1172/JCI161858.
    Full Text Link to Item
  - Seale, Katelyn Nazaneen, Matthew K. Labriola, Xiaoyin Sara Jiang, and Andrew Armstrong. “Remission of progressive metastatic castration-resistant prostate cancer during abiraterone therapy following unilateral adrenalectomy for a functioning adrenal adenoma.” Bmj Case Rep 15, no. 10 (October 5, 2022). https://doi.org/10.1136/bcr-2022-251036.
    Full Text Link to Item
  - Bu, Jiyoon, Woo-Jin Jeong, Roya Jafari, Luke J. Kubiatowicz, Ashita Nair, Michael J. Poellmann, Rachel S. Hong, et al. “Bimodal liquid biopsy for cancer immunotherapy based on peptide engineering and nanoscale analysis.” Biosens Bioelectron 213 (October 1, 2022): 114445. https://doi.org/10.1016/j.bios.2022.114445.
    Full Text Link to Item
  - Morris, Michael J., Jose Mauricio Mota, Kristine Lacuna, Patrick Hilden, Martin Gleave, Michael A. Carducci, Fred Saad, et al. “Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4:543-52].” Eur Urol Oncol 5, no. 5 (October 2022): 603. https://doi.org/10.1016/j.euo.2022.08.001.
    Full Text Link to Item
  - Aggarwal, Rahul, Alexander N. Starodub, Brian D. Koh, Guan Xing, Andrew J. Armstrong, and Michael A. Carducci. “Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer.” Clin Cancer Res 28, no. 18 (September 15, 2022): 3979–89. https://doi.org/10.1158/1078-0432.CCR-22-0175.
    Full Text Link to Item
  - Koshkin, Vadim S., Vaibhav G. Patel, Alicia Ali, Mehmet A. Bilen, Deepak Ravindranathan, Joseph J. Park, Olesia Kellezi, et al. “PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer.” Prostate Cancer Prostatic Dis 25, no. 3 (September 2022): 388–96. https://doi.org/10.1038/s41391-021-00433-1.
    Full Text Link to Item
  - Penson, David F., Andrew J. Armstrong, Raoul S. Concepcion, Neeraj Agarwal, Carl A. Olsson, Lawrence I. Karsh, Curtis J. Dunshee, et al. “Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.” Prostate Cancer Prostatic Dis 25, no. 3 (September 2022): 597. https://doi.org/10.1038/s41391-021-00477-3.
    Full Text Link to Item
  - Stenzl, Arnulf, Russell Z. Szmulewitz, Daniel Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Arun Azad, Antonio Alcaraz, et al. “The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.” Prostate 82, no. 13 (September 2022): 1237–47. https://doi.org/10.1002/pros.24396.
    Full Text Link to Item
  - Michael, Zoe D., Srinath Kotamarti, Rohith Arcot, Kostantinos Morris, Anand Shah, John Anderson, Andrew J. Armstrong, et al. “Initial Longitudinal Outcomes of Risk-Stratified Men in Their Forties Screened for Prostate Cancer Following Implementation of a Baseline Prostate-Specific Antigen.” World J Mens Health, August 16, 2022. https://doi.org/10.5534/wjmh.220068.
    Full Text Link to Item
  - Chen, Yu-Wei, Matthew D. Tucker, Landon C. Brown, Hesham A. Yasin, Kristin K. Ancell, Andrew J. Armstrong, Kathryn E. Beckermann, et al. “The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma.” Cancers 14, no. 15 (August 2022): 3830. https://doi.org/10.3390/cancers14153830.
    Full Text
  - Fizazi, Karim, Margitta Retz, Daniel P. Petrylak, Jeffrey C. Goh, Jose Perez-Gracia, Louis Lacombe, Stefanie Zschäbitz, et al. “Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial.” J Immunother Cancer 10, no. 8 (August 2022). https://doi.org/10.1136/jitc-2022-004761.
    Full Text Link to Item
  - Dzimitrowicz, Hannah E., and Andrew J. Armstrong. “Reply to L. Marandino et al.” J Clin Oncol 40, no. 19 (July 1, 2022): 2175–76. https://doi.org/10.1200/JCO.22.00337.
    Full Text Link to Item
  - Gillessen, Silke, Andrew Armstrong, Gert Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, et al. “Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.” Eur Urol 82, no. 1 (July 2022): 115–41. https://doi.org/10.1016/j.eururo.2022.04.002.
    Full Text Link to Item
  - Joshua, Anthony M., Andrew Armstrong, Megan Crumbaker, Howard I. Scher, Johann de Bono, Bertrand Tombal, Maha Hussain, et al. “Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER.” Eur J Cancer 170 (July 2022): 285–95. https://doi.org/10.1016/j.ejca.2022.04.005.
    Full Text Link to Item
  - Turco, Fabio, Andrew Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, et al. “What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.” Eur Urol 82, no. 1 (July 2022): 6–11. https://doi.org/10.1016/j.eururo.2022.02.010.
    Full Text Link to Item
  - Turco, Fabio, Andrew Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, et al. “Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11].” Eur Urol 82, no. 1 (July 2022): e18–19. https://doi.org/10.1016/j.eururo.2022.04.004.
    Full Text Link to Item
  - Wilson, Brooke E., Andrew J. Armstrong, Johann de Bono, Cora N. Sternberg, Charles J. Ryan, Howard I. Scher, Matthew R. Smith, et al. “Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302.” Eur J Cancer 170 (July 2022): 296–304. https://doi.org/10.1016/j.ejca.2022.03.042.
    Full Text Link to Item
  - Coombes, R. C., P. D. Badman, J. P. Lozano-Kuehne, X. Liu, I. R. Macpherson, I. Zubairi, R. D. Baird, et al. “Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer.” Nat Commun 13, no. 1 (June 10, 2022): 3246. https://doi.org/10.1038/s41467-022-30666-0.
    Full Text Link to Item
  - Ardolino, L. C., R. Dear, A. J. Armstrong, S. Gillessen, and A. M. Joshua. “Clinical trials for metastatic castrate-resistant prostate cancer-who is looking after the control patients? Questions for the future.” Ann Oncol 33, no. 6 (June 2022): 574–77. https://doi.org/10.1016/j.annonc.2022.03.272.
    Full Text Link to Item
  - Armstrong, Andrew J., Arun A. Azad, Taro Iguchi, Russell Z. Szmulewitz, Daniel P. Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, et al. “Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.” J Clin Oncol 40, no. 15 (May 20, 2022): 1616–22. https://doi.org/10.1200/JCO.22.00193.
    Full Text Link to Item
  - Chi, Kim N. “Update on metastatic hormone-sensitive prostate cancer.” Clin Adv Hematol Oncol 20, no. 5 (May 2022): 277–80.
    Link to Item
  - Zhang, Tian, Julie Kephart, Elizabeth Bronson, Monika Anand, Christine Daly, Ivan Spasojevic, Subha Bakthavatsalam, et al. “Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer.” Prostate 82, no. 7 (May 2022): 858–66. https://doi.org/10.1002/pros.24329.
    Full Text Link to Item
  - Armstrong, Andrew J. “Highlights in advanced prostate cancer from the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium: commentary.” Clin Adv Hematol Oncol 20 Suppl 8, no. 4 (April 2022): 16–22.
    Link to Item
  - Brown, Landon C., Susan Halabi, Jason A. Somarelli, Michael Humeniuk, Yuan Wu, Taofik Oyekunle, Lauren Howard, et al. “A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer.” Prostate Cancer Prostatic Dis 25, no. 4 (April 2022): 762–69. https://doi.org/10.1038/s41391-022-00524-7.
    Full Text Link to Item
  - De Nunzio, Cosimo, Andrew J. Amstrong, Inge Van Oort, and Tanya Dorff. “Editor' summary: A paradigm shift in castration-resistant prostate cancer management.” Prostate Cancer Prostatic Dis 25, no. 4 (April 2022): 601–3. https://doi.org/10.1038/s41391-022-00574-x.
    Full Text Link to Item
  - Hawkey, Nathan M., Alton O. Sartor, Michael J. Morris, and Andrew J. Armstrong. “Prostate-specific membrane antigen-targeted theranostics: past, present, and future approaches.” Clin Adv Hematol Oncol 20, no. 4 (April 2022): 227–38.
    Link to Item
  - Dzimitrowicz, Hannah E., and Andrew J. Armstrong. “Elevating the Patient Voice in Metastatic Hormone-Sensitive Prostate Cancer Clinical Trials.” J Clin Oncol 40, no. 8 (March 10, 2022): 807–10. https://doi.org/10.1200/JCO.21.02504.
    Full Text Link to Item
  - Harrison, Michael R., Paul G. Davis, Michel G. Khouri, David B. Bartlett, Rajan T. Gupta, Andrew J. Armstrong, Megan A. McNamara, et al. “A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND).” Prostate Cancer Prostatic Dis 25, no. 1 (March 2022): 58–64. https://doi.org/10.1038/s41391-022-00519-4.
    Full Text Link to Item
  - Zhao, Jimmy L., Karim Fizazi, Fred Saad, Kim N. Chi, Mary-Ellen Taplin, Cora N. Sternberg, Andrew J. Armstrong, Johann S. de Bono, William T. Duggan, and Howard I. Scher. “The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 28, no. 5 (March 2022): 860–69. https://doi.org/10.1158/1078-0432.ccr-21-1090.
    Full Text
  - Sperger, Jamie M., Felix Y. Feng, Andrew J. Armstrong, Shuang G. Zhao, and Joshua M. Lang. “Reply to M. K. Bos et al.” J Clin Oncol 40, no. 5 (February 10, 2022): 520–22. https://doi.org/10.1200/JCO.21.02238.
    Full Text Link to Item
  - Azad, Arun A., Andrew J. Armstrong, Antonio Alcaraz, Russell Z. Szmulewitz, Daniel P. Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, et al. “Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk.” Prostate Cancer Prostatic Dis 25, no. 2 (February 2022): 274–82. https://doi.org/10.1038/s41391-021-00436-y.
    Full Text Link to Item
  - Penson, David F., Andrew J. Armstrong, Raoul S. Concepcion, Neeraj Agarwal, Carl A. Olsson, Lawrence I. Karsh, Curtis J. Dunshee, et al. “Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.” Prostate Cancer Prostatic Dis 25, no. 2 (February 2022): 363–65. https://doi.org/10.1038/s41391-021-00465-7.
    Full Text Link to Item
  - Tombal, Bertrand F., Stephen J. Freedland, Andrew J. Armstrong, Tomasz M. Beer, Arnulf Stenzl, Cora N. Sternberg, Maha Hussain, et al. “Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials.” Prostate Cancer Prostatic Dis 25, no. 2 (February 2022): 288–95. https://doi.org/10.1038/s41391-021-00447-9.
    Full Text Link to Item
  - Fizazi, Karim, Pablo González Mella, Daniel Castellano, Jose N. Minatta, Arash Rezazadeh Kalebasty, David Shaffer, Juan C. Vázquez Limón, et al. “Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial.” Eur J Cancer 160 (January 2022): 61–71. https://doi.org/10.1016/j.ejca.2021.09.043.
    Full Text Link to Item
  - Kang, Yubin, Andrew J. Armstrong, and David S. Hsu. “An autologous humanized patient-derived xenograft (PDX) model for evaluation of nivolumab immunotherapy in renal cell cancer: a case report.” Stem Cell Investigation 9 (January 2022): 8. https://doi.org/10.21037/sci-2022-029.
    Full Text
  - Autio, Karen A., Emmanuel S. Antonarakis, Tina M. Mayer, Daniel H. Shevrin, Mark N. Stein, Ulka N. Vaishampayan, Michael J. Morris, et al. “Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.” Eur Urol Open Sci 34 (December 2021): 70–78. https://doi.org/10.1016/j.euros.2021.09.015.
    Full Text Link to Item
  - Bitting, Rhonda L., Patrick Healy, Daniel J. George, Monika Anand, Sung Kim, Tina Mayer, Carol Winters, et al. “Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial.” Eur Urol Oncol 4, no. 6 (December 2021): 948–54. https://doi.org/10.1016/j.euo.2020.01.005.
    Full Text Link to Item
  - Tombal, Bertrand, Arnulf Stenzl, David Cella, Yohann Loriot, Andrew J. Armstrong, Karim Fizazi, Tomasz Beer, et al. “The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials.” Cancers (Basel) 13, no. 23 (November 23, 2021). https://doi.org/10.3390/cancers13235872.
    Full Text Link to Item
  - Tucker, Matthew D., Landon C. Brown, Yu-Wei Chen, Chester Kao, Nathan Hirshman, Emily N. Kinsey, Kristin K. Ancell, et al. “Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma.” Biomark Res 9, no. 1 (November 3, 2021): 80. https://doi.org/10.1186/s40364-021-00334-4.
    Full Text Link to Item
  - Armstrong, Andrew J. “The role of AR-V7 testing in the management of metastatic CRPC.” Clin Adv Hematol Oncol 19, no. 11 (November 2021): 694–97.
    Link to Item
  - Schmidt, Andrew L., Matthew D. Tucker, Ziad Bakouny, Chris Labaki, Chih-Yuan Hsu, Yu Shyr, Andrew J. Armstrong, et al. “Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19.” Jama Netw Open 4, no. 11 (November 1, 2021): e2134330. https://doi.org/10.1001/jamanetworkopen.2021.34330.
    Full Text Link to Item
  - Halabi, Susan, Qian Yang, Andrea Carmack, Shiqi Zhang, Wen-Chi Foo, Tim Eisen, Walter M. Stadler, et al. “Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial.” Kidney Cancer J 19, no. 3 (October 2021): 64–72. https://doi.org/10.52733/kcj19n3-a1.
    Full Text Link to Item
  - Sperger, Jamie M., Hamid Emamekhoo, Rana R. McKay, Charlotte N. Stahlfeld, Anupama Singh, Xinyi E. Chen, Lucia Kwak, et al. “Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer.” J Clin Oncol 39, no. 26 (September 10, 2021): 2926–37. https://doi.org/10.1200/JCO.21.00169.
    Full Text Link to Item
  - Armstrong, Andrew J., Xiaotong Li, Matthew Tucker, Shantao Li, Xinmeng Jasmine Mu, Kenneth Wha Eng, Andrea Sboner, Mark Rubin, and Mark Gerstein. “Molecular medicine tumor board: whole-genome sequencing to inform on personalized medicine for a man with advanced prostate cancer.” Prostate Cancer Prostatic Dis 24, no. 3 (September 2021): 786–93. https://doi.org/10.1038/s41391-021-00324-5.
    Full Text Link to Item
  - Fong, Lawrence, Michael J. Morris, Oliver Sartor, Celestia S. Higano, Lance Pagliaro, Ajjai Alva, Leonard J. Appleman, et al. “A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer.” Clin Cancer Res 27, no. 17 (September 1, 2021): 4746–56. https://doi.org/10.1158/1078-0432.CCR-21-0063.
    Full Text Link to Item
  - George, Daniel J., Susan Halabi, Elisabeth I. Heath, A Oliver Sartor, Guru P. Sonpavde, Devika Das, Rhonda L. Bitting, et al. “A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.” Cancer 127, no. 16 (August 15, 2021): 2954–65. https://doi.org/10.1002/cncr.33589.
    Full Text Link to Item
  - Armstrong, Andrew J. “Highlights in advanced prostate cancer from the 2021 American Society of Clinical Oncology Annual Meeting: commentary.” Clin Adv Hematol Oncol 19 Suppl 18, no. 8 (August 2021): 18–23.
    Link to Item
  - Morris, Michael J., Jose Mauricio Mota, Kristine Lacuna, Patrick Hilden, Martin Gleave, Michael A. Carducci, Fred Saad, et al. “Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503).” Eur Urol Oncol 4, no. 4 (August 2021): 543–52. https://doi.org/10.1016/j.euo.2021.04.008.
    Full Text Link to Item
  - Brown, Landon C., Susan Halabi, Joseph D. Schonhoft, Qian Yang, Jun Luo, David M. Nanus, Paraskevi Giannakakou, et al. “Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide.” Clin Cancer Res 27, no. 14 (July 15, 2021): 4077–88. https://doi.org/10.1158/1078-0432.CCR-20-3471.
    Full Text Link to Item
  - Iguchi, Taro, Go Kimura, Satoshi Fukasawa, Hiroyoshi Suzuki, Hiroji Uemura, Kazuo Nishimura, Hiroaki Matsumoto, et al. “Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study.” Int J Urol 28, no. 7 (July 2021): 765–73. https://doi.org/10.1111/iju.14568.
    Full Text Link to Item
  - Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma.” Clin Cancer Res 27, no. 12 (June 15, 2021): 3317–28. https://doi.org/10.1158/1078-0432.CCR-20-4504.
    Full Text Link to Item
  - Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non-Clear Cell Renal Cell Carcinoma.” Clin Cancer Res 27, no. 12 (June 15, 2021): 3503. https://doi.org/10.1158/1078-0432.CCR-21-1636.
    Full Text Link to Item
  - Hawkey, Nathan M., and Andrew J. Armstrong. “Liquid Biopsy: It's the Bloody Truth!.” Clin Cancer Res 27, no. 11 (June 1, 2021): 2961–63. https://doi.org/10.1158/1078-0432.CCR-21-0531.
    Full Text Link to Item
  - Scher, H. I., A. J. Armstrong, J. D. Schonhoft, A. Gill, J. L. Zhao, E. Barnett, E. Carbone, et al. “Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.” Eur J Cancer 150 (June 2021): 83–94. https://doi.org/10.1016/j.ejca.2021.02.042.
    Full Text Link to Item
  - Armstrong, Andrew J., Neal D. Shore, Russell Z. Szmulewitz, Daniel P. Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Arun Azad, et al. “Reply by Authors.” J Urol 205, no. 5 (May 2021): 1371. https://doi.org/10.1097/JU.0000000000001568.02.
    Full Text Link to Item
  - Halabi, Susan, and Andrew J. Armstrong. “Sarcomatoid Renal Cell Carcinoma: An Immune Checkpoint-responsive Subset?” Eur Urol 79, no. 5 (May 2021): 663–64. https://doi.org/10.1016/j.eururo.2021.01.042.
    Full Text Link to Item
  - Armstrong, A. J. “Highlights in Advanced Prostate Cancer From the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium: A Review of Selected Presentations From the All-Virtual Genitourinary Cancers Symposium February 11-13, 2021.” Clinical Advances in Hematology and Oncology 19, no. 4 (April 1, 2021).
  - Armstrong, Andrew J. “Highlights in advanced prostate cancer from the 2021 Genitourinary Cancers Symposium: commentary.” Clin Adv Hematol Oncol 19 Suppl 15, no. 4 (April 2021): 20–23.
    Link to Item
  - Koontz, Bridget F., Karen E. Hoffman, Susan Halabi, Patrick Healy, Monika Anand, Daniel J. George, Michael R. Harrison, et al. “Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer.” Int J Radiat Oncol Biol Phys 109, no. 5 (April 1, 2021): 1271–78. https://doi.org/10.1016/j.ijrobp.2020.11.059.
    Full Text Link to Item
  - Laccetti, Andrew L., Benjamin Garmezy, Lianchun Xiao, Minas Economides, Aradhana Venkatesan, Jianjun Gao, Eric Jonasch, et al. “Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.” Cancer Med 10, no. 7 (April 2021): 2341–49. https://doi.org/10.1002/cam4.3812.
    Full Text Link to Item
  - Freedland, Stephen J., Jenifer Allen, Aubrey Jarman, Taofik Oyekunle, Andrew J. Armstrong, Judd W. Moul, Howard M. Sandler, et al. “Correction: A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2).” Clin Cancer Res 27, no. 6 (March 15, 2021): 1823. https://doi.org/10.1158/1078-0432.CCR-21-0372.
    Full Text Link to Item
  - Marshall, Catherine H., Wei Fu, Hao Wang, Jong Chul Park, Theodore L. DeWeese, Phuoc T. Tran, Daniel Y. Song, et al. “Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer.” Clin Cancer Res 27, no. 6 (March 15, 2021): 1623–30. https://doi.org/10.1158/1078-0432.CCR-20-4476.
    Full Text Link to Item
  - Brown, Landon C., Matthew D. Tucker, Ramy Sedhom, Eric B. Schwartz, Jason Zhu, Chester Kao, Matthew K. Labriola, et al. “LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types.” J Immunother Cancer 9, no. 3 (March 2021). https://doi.org/10.1136/jitc-2020-001792.
    Full Text Open Access Copy Link to Item
  - Zhang, Tian, Anika Agarwal, R Garland Almquist, Daniella Runyambo, Sally Park, Elizabeth Bronson, Rengasamy Boominathan, et al. “Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer.” Biomark Res 9, no. 1 (February 18, 2021): 14. https://doi.org/10.1186/s40364-021-00267-y.
    Full Text Link to Item
  - Schaeffer, Edward, Sandy Srinivas, Emmanuel S. Antonarakis, Andrew J. Armstrong, Justin E. Bekelman, Heather Cheng, Anthony Victor D’Amico, et al. “NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.” J Natl Compr Canc Netw 19, no. 2 (February 2, 2021): 134–43. https://doi.org/10.6004/jnccn.2021.0008.
    Full Text Link to Item
  - Chakraborty, Priyanka, Emily L. Chen, Isabelle McMullen, Andrew J. Armstrong, Mohit Kumar Jolly, and Jason A. Somarelli. “Analysis of immune subtypes across the epithelial-mesenchymal plasticity spectrum.” Comput Struct Biotechnol J 19 (2021): 3842–51. https://doi.org/10.1016/j.csbj.2021.06.023.
    Full Text Link to Item
  - Brown, Landon C., Jason Zhu, Matthew K. Labriola, Yuan Wu, Sachica Cheris, Xin Liu, Kathryn Perkinson, et al. “PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma.” Clin Genitourin Cancer 18, no. 6 (December 2020): 509–13. https://doi.org/10.1016/j.clgc.2020.03.020.
    Full Text Link to Item
  - Koontz, Bridget F. “The role of radiation treatment in metastatic prostate cancer.” Clin Adv Hematol Oncol 18, no. 11 (November 2020): 707–9.
    Link to Item
  - Villers, A., N. Shore, A. Armstrong, R. Szmulewitz, D. Petrylak, J. Holzbeierlein, A. Azad, et al. “Efficacité de l’enzalutamide (ENZA) + traitement par suppression androgénique (TSA) dans le cancer de la prostate hormonosensible métastatique (mHSPC) en fonction de la localisation des métastases : analyses post-hoc de l’étude ARCHES.” Prog Urol 30, no. 13 (November 2020): 745. https://doi.org/10.1016/j.purol.2020.07.091.
    Full Text Link to Item
  - Powers, Eric, Georgia Sofia Karachaliou, Chester Kao, Michael R. Harrison, Christopher J. Hoimes, Daniel J. George, Andrew J. Armstrong, and Tian Zhang. “Novel therapies are changing treatment paradigms in metastatic prostate cancer.” J Hematol Oncol 13, no. 1 (October 28, 2020): 144. https://doi.org/10.1186/s13045-020-00978-z.
    Full Text Link to Item
  - Stenzl, Arnulf, Curtis Dunshee, Ugo De Giorgi, Boris Alekseev, Taro Iguchi, Russell Z. Szmulewitz, Thomas W. Flaig, et al. “Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study.” Eur Urol 78, no. 4 (October 2020): 603–14. https://doi.org/10.1016/j.eururo.2020.03.019.
    Full Text Link to Item
  - Armstrong, Andrew J., Ping Lin, Bertrand Tombal, Fred Saad, Celestia S. Higano, Anthony M. Joshua, Teresa Parli, Brad Rosbrook, Steve van Os, and Tomasz M. Beer. “Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial.” Eur Urol 78, no. 3 (September 2020): 347–57. https://doi.org/10.1016/j.eururo.2020.04.061.
    Full Text Link to Item
  - Brown, Landon C., Changxue Lu, Emmanuel S. Antonarakis, Jun Luo, and Andrew J. Armstrong. “Androgen receptor variant-driven prostate cancer II: advances in clinical investigation.” Prostate Cancer Prostatic Dis 23, no. 3 (September 2020): 367–80. https://doi.org/10.1038/s41391-020-0215-5.
    Full Text Link to Item
  - Lu, Changxue, Landon C. Brown, Emmanuel S. Antonarakis, Andrew J. Armstrong, and Jun Luo. “Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations.” Prostate Cancer Prostatic Dis 23, no. 3 (September 2020): 381–97. https://doi.org/10.1038/s41391-020-0217-3.
    Full Text Link to Item
  - Sartor, Oliver, Andrew J. Armstrong, Chiledum Ahaghotu, David G. McLeod, Matthew R. Cooperberg, David F. Penson, Philip W. Kantoff, et al. “Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry.” Prostate Cancer Prostatic Dis 23, no. 3 (September 2020): 517–26. https://doi.org/10.1038/s41391-020-0213-7.
    Full Text Link to Item
  - Bu, Jiyoon, Ashita Nair, Luke J. Kubiatowicz, Michael J. Poellmann, Woo-Jin Jeong, Marco Reyes-Martinez, Andrew J. Armstrong, et al. “Surface engineering for efficient capture of circulating tumor cells in renal cell carcinoma: From nanoscale analysis to clinical application.” Biosens Bioelectron 162 (August 15, 2020): 112250. https://doi.org/10.1016/j.bios.2020.112250.
    Full Text Link to Item
  - Wu, Mengxi, Po-Hsun Huang, Rui Zhang, Zhangming Mao, Chuyi Chen, Gabor Kemeny, Peng Li, et al. “Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation.” Small 16, no. 34 (August 2020): e2004438. https://doi.org/10.1002/smll.202004438.
    Full Text Link to Item
  - Freedland, Stephen J., Jenifer Allen, Aubrey Jarman, Taofik Oyekunle, Andrew J. Armstrong, Judd W. Moul, Howard M. Sandler, et al. “A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2).” Clin Cancer Res 26, no. 12 (June 15, 2020): 3035–43. https://doi.org/10.1158/1078-0432.CCR-19-3873.
    Full Text Link to Item
  - Higano, Celestia S., Andrew J. Armstrong, Oliver Sartor, Nicholas J. Vogelzang, Philip W. Kantoff, David G. McLeod, Christopher M. Pieczonka, et al. “Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data.” Cancer 126, no. 12 (June 15, 2020): 2935–37. https://doi.org/10.1002/cncr.32785.
    Full Text Link to Item
  - Eggener, Scott E., R Bryan Rumble, Andrew J. Armstrong, Todd M. Morgan, Tony Crispino, Philip Cornford, Theodorus van der Kwast, et al. “Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline.” J Clin Oncol 38, no. 13 (May 1, 2020): 1474–94. https://doi.org/10.1200/JCO.19.02768.
    Full Text Link to Item
  - Gupta, Santosh, Daniel H. Hovelson, Gabor Kemeny, Susan Halabi, Wen-Chi Foo, Monika Anand, Jason A. Somarelli, et al. “Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.” Genes Chromosomes Cancer 59, no. 4 (April 2020): 225–39. https://doi.org/10.1002/gcc.22824.
    Full Text Link to Item
  - George, Daniel J., Susan Halabi, Patrick Healy, Darius Jonasch, Monika Anand, Julia Rasmussen, Sarah Y. Wood, Charles Spritzer, John F. Madden, and Andrew J. Armstrong. “Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer.” Urol Oncol 38, no. 3 (March 2020): 79.e15-79.e22. https://doi.org/10.1016/j.urolonc.2019.08.015.
    Full Text Link to Item
  - Armstrong, Andrew J., Mohammed Al-Adhami, Ping Lin, Teresa Parli, Jennifer Sugg, Joyce Steinberg, Bertrand Tombal, et al. “Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials.” Jama Oncol 6, no. 2 (February 1, 2020): 217–25. https://doi.org/10.1001/jamaoncol.2019.4636.
    Full Text Link to Item
  - Brown, Landon C., and Andrew J. Armstrong. “Has Mismatch Repair-Deficient Cancer Met Its MATCH?” J Clin Oncol 38, no. 3 (January 20, 2020): 183–87. https://doi.org/10.1200/JCO.19.02860.
    Full Text Link to Item
  - Armstrong, Andrew J., Jun Luo, David M. Nanus, Paraskevi Giannakakou, Russell Z. Szmulewitz, Daniel C. Danila, Patrick Healy, et al. “Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer.” Jco Precis Oncol 4 (2020). https://doi.org/10.1200/PO.20.00200.
    Full Text Link to Item
  - Kinsey, Emily N., Tian Zhang, and Andrew J. Armstrong. “Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape.” Cancer J 26, no. 1 (2020): 64–75. https://doi.org/10.1097/PPO.0000000000000418.
    Full Text Link to Item
  - Li, Yanjing, Yiping He, William Butler, Lingfan Xu, Yan Chang, Kefeng Lei, Hong Zhang, et al. “Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer.” Sci Transl Med 11, no. 521 (December 4, 2019). https://doi.org/10.1126/scitranslmed.aax0428.
    Full Text Link to Item
  - Higano, Celestia S., Andrew J. Armstrong, A Oliver Sartor, Nicholas J. Vogelzang, Philip W. Kantoff, David G. McLeod, Christopher M. Pieczonka, et al. “Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.” Cancer 125, no. 23 (December 1, 2019): 4172–80. https://doi.org/10.1002/cncr.32445.
    Full Text Link to Item
  - Holl, Eda K., Megan A. McNamara, Patrick Healy, Monika Anand, Raoul S. Concepcion, Coleman D. Breland, Igor Dumbudze, et al. “Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients.” Prostate Cancer Prostatic Dis 22, no. 4 (December 2019): 588–92. https://doi.org/10.1038/s41391-019-0144-3.
    Full Text Link to Item
  - Mota, Jose Mauricio, Andrew J. Armstrong, Steven M. Larson, Josef J. Fox, and Michael J. Morris. “Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials.” Prostate Cancer Prostatic Dis 22, no. 4 (December 2019): 522–30. https://doi.org/10.1038/s41391-019-0151-4.
    Full Text Link to Item
  - Armstrong, Andrew J., Russell Z. Szmulewitz, Daniel P. Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Arun Azad, Antonio Alcaraz, et al. “ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.” J Clin Oncol 37, no. 32 (November 10, 2019): 2974–86. https://doi.org/10.1200/JCO.19.00799.
    Full Text Link to Item
  - Yuan, Fuwen, William Hankey, Dayong Wu, Hongyan Wang, Jason Somarelli, Andrew J. Armstrong, Jiaoti Huang, Zhong Chen, and Qianben Wang. “Molecular determinants for enzalutamide-induced transcription in prostate cancer.” Nucleic Acids Res 47, no. 19 (November 4, 2019): 10104–14. https://doi.org/10.1093/nar/gkz790.
    Full Text Open Access Copy Link to Item
  - Armstrong, Andrew J., Ping Lin, Celestia S. Higano, Peter Iversen, Cora N. Sternberg, Bertrand Tombal, De Phung, Teresa Parli, Andrew Krivoshik, and Tomasz M. Beer. “Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.” Eur Urol Oncol 2, no. 6 (November 2019): 677–84. https://doi.org/10.1016/j.euo.2018.11.005.
    Full Text Link to Item
  - George, Daniel J., Susan Halabi, Patrick Healy, Ian Barak, Carolyn Winters, Monika Anand, Rhonda Wilder, et al. “Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.” Prostate 79, no. 15 (November 2019): 1752–61. https://doi.org/10.1002/pros.23899.
    Full Text Link to Item
  - Zhu, Jason, Matthew Tucker, Daniele Marin, Rajan T. Gupta, Patrick Healy, Michael Humeniuk, Casey Jarvis, et al. “Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer.” Urol Oncol 37, no. 11 (November 2019): 813.e1-813.e9. https://doi.org/10.1016/j.urolonc.2019.06.015.
    Full Text Link to Item
  - Freedland, Stephen J., Lauren Howard, Jenifer Allen, Jordan Smith, Jennifer Stout, William Aronson, Brant A. Inman, et al. “A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial.” Prostate Cancer Prostatic Dis 22, no. 3 (September 2019): 428–37. https://doi.org/10.1038/s41391-019-0126-5.
    Full Text Open Access Copy Link to Item
  - Armstrong, Andrew J., Susan Halabi, Jun Luo, David M. Nanus, Howard I. Scher, Emmanuel S. Antonarakis, and Daniel J. George. “Reply to L. Dirix, B. De Laere et al, and A. Sharp et al.” J Clin Oncol 37, no. 24 (August 20, 2019): 2184–86. https://doi.org/10.1200/JCO.19.01230.
    Full Text Link to Item
  - Tucker, Matthew D., Jason Zhu, Daniele Marin, Rajan T. Gupta, Santosh Gupta, William R. Berry, Sundhar Ramalingam, et al. “Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer.” Cancer Med 8, no. 10 (August 2019): 4644–55. https://doi.org/10.1002/cam4.2375.
    Full Text Link to Item
  - McNamara, Megan Ann, Taofik Oyekunle, Bennett B. Chin, Jorge Oldan, Aseem Anand, Michala Ritz, Lindsey Shantzer, Monika Anand, Andrew J. Armstrong, and Daniel J. George. “Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer.” Prostate 79, no. 10 (July 2019): 1106–16. https://doi.org/10.1002/pros.23822.
    Full Text Link to Item
  - Jolly, Mohit Kumar, Kathryn E. Ware, Shengnan Xu, Shivee Gilja, Samantha Shetler, Yanjun Yang, Xueyang Wang, et al. “E-Cadherin Represses Anchorage-Independent Growth in Sarcomas through Both Signaling and Mechanical Mechanisms.” Mol Cancer Res 17, no. 6 (June 2019): 1391–1402. https://doi.org/10.1158/1541-7786.MCR-18-0763.
    Full Text Link to Item
  - Labriola, Matthew K., Kristen A. Batich, Jason Zhu, Megan A. McNamara, Michael R. Harrison, Andrew J. Armstrong, Daniel J. George, and Tian Zhang. “Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.” Clin Genitourin Cancer 17, no. 3 (June 2019): e513–21. https://doi.org/10.1016/j.clgc.2019.01.017.
    Full Text Link to Item
  - Mohler, James L., Emmanuel S. Antonarakis, Andrew J. Armstrong, Anthony V. D’Amico, Brian J. Davis, Tanya Dorff, James A. Eastham, et al. “Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 17, no. 5 (May 1, 2019): 479–505. https://doi.org/10.6004/jnccn.2019.0023.
    Full Text Link to Item
  - Armstrong, Andrew J., Susan Halabi, Jun Luo, David M. Nanus, Paraskevi Giannakakou, Russell Z. Szmulewitz, Daniel C. Danila, et al. “Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.” J Clin Oncol 37, no. 13 (May 1, 2019): 1120–29. https://doi.org/10.1200/JCO.18.01731.
    Full Text Link to Item
  - Sonpavde, Guru, Neeraj Agarwal, Gregory Russell Pond, Rebecca J. Nagy, Roberto H. Nussenzveig, Andrew W. Hahn, Oliver Sartor, et al. “Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.” Cancer 125, no. 9 (May 1, 2019): 1459–69. https://doi.org/10.1002/cncr.31959.
    Full Text Link to Item
  - Xu, Shengnan, Kathryn E. Ware, Yuantong Ding, So Young Kim, Maya U. Sheth, Sneha Rao, Wesley Chan, et al. “An Integrative Systems Biology and Experimental Approach Identifies Convergence of Epithelial Plasticity, Metabolism, and Autophagy to Promote Chemoresistance.” J Clin Med 8, no. 2 (February 7, 2019). https://doi.org/10.3390/jcm8020205.
    Full Text Link to Item
  - Armstrong, Andrew J., Orjan Nordle, and Michael Morris. “Assessing the Prognostic Value of the Automated Bone Scan Index for Prostate Cancer-Reply.” Jama Oncol 5, no. 2 (February 1, 2019): 270–71. https://doi.org/10.1001/jamaoncol.2018.5874.
    Full Text Link to Item
  - Jolly, Mohit Kumar, Jason A. Somarelli, Maya Sheth, Adrian Biddle, Satyendra C. Tripathi, Andrew J. Armstrong, Samir M. Hanash, Sharmila A. Bapat, Annapoorni Rangarajan, and Herbert Levine. “Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas.” Pharmacol Ther 194 (February 2019): 161–84. https://doi.org/10.1016/j.pharmthera.2018.09.007.
    Full Text Link to Item
  - Zhang, Tian, Daniel J. George, and Andrew J. Armstrong. “Precision Medicine Approaches When Prostate Cancer Akts Up.” Clin Cancer Res 25, no. 3 (February 1, 2019): 901–3. https://doi.org/10.1158/1078-0432.CCR-18-2491.
    Full Text Link to Item
  - Armstrong, Andrew J., Santosh Gupta, Patrick Healy, Gabor Kemeny, Beth Leith, Michael R. Zalutsky, Charles Spritzer, et al. “Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.” Plos One 14, no. 5 (2019): e0216934. https://doi.org/10.1371/journal.pone.0216934.
    Full Text Link to Item
  - Beltran, Himisha, Clara Oromendia, Daniel C. Danila, Bruce Montgomery, Christopher Hoimes, Russell Z. Szmulewitz, Ulka Vaishampayan, et al. “A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.” Clin Cancer Res 25, no. 1 (January 1, 2019): 43–51. https://doi.org/10.1158/1078-0432.CCR-18-1912.
    Full Text Link to Item
  - Zhang, Tian, Andrew J. Armstrong, Daniel J. George, and Jiaoti Huang. “The promise of immunotherapy in genitourinary malignancies.” Precis Clin Med 1, no. 3 (December 2018): 97–101. https://doi.org/10.1093/pcmedi/pby018.
    Full Text Link to Item
  - Armstrong, A. J., P. Lin, C. S. Higano, C. N. Sternberg, G. Sonpavde, B. Tombal, A. J. Templeton, et al. “Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.” Ann Oncol 29, no. 11 (November 1, 2018): 2200–2207. https://doi.org/10.1093/annonc/mdy406.
    Full Text Link to Item
  - Armstrong, Andrew J. “Updates in advanced prostate cancer 2018.” Prostate Cancer Prostatic Dis 21, no. 4 (November 2018): 449–50. https://doi.org/10.1038/s41391-018-0100-7.
    Full Text Link to Item
  - Brown, Landon C., Guru Sonpavde, and Andrew J. Armstrong. “Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?” Prostate Cancer Prostatic Dis 21, no. 3 (September 2018): 419–30. https://doi.org/10.1038/s41391-018-0049-6.
    Full Text Link to Item
  - McNamara, Megan, Christopher Sweeney, Emmanuel S. Antonarakis, and Andrew J. Armstrong. “The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.” Prostate Cancer Prostatic Dis 21, no. 3 (September 2018): 306–18. https://doi.org/10.1038/s41391-017-0014-9.
    Full Text Link to Item
  - Wu, Mengxi, Po-Hsun Huang, Rui Zhang, Zhangming Mao, Chuyi Chen, Gabor Kemeny, Peng Li, et al. “Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation.” Small 14, no. 32 (August 2018): e1801131. https://doi.org/10.1002/smll.201801131.
    Full Text Link to Item
  - Armstrong, Andrew J., Aseem Anand, Lars Edenbrandt, Eva Bondesson, Anders Bjartell, Anders Widmark, Cora N. Sternberg, et al. “Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.” Jama Oncol 4, no. 7 (July 1, 2018): 944–51. https://doi.org/10.1001/jamaoncol.2018.1093.
    Full Text Link to Item
  - Fantony, Joseph J., Lauren E. Howard, Ilona Csizmadi, Andrew J. Armstrong, Amy L. Lark, Colette Galet, William J. Aronson, and Stephen J. Freedland. “Is Ki67 prognostic for aggressive prostate cancer? A multicenter real-world study.” Biomark Med 12, no. 7 (July 2018): 727–36. https://doi.org/10.2217/bmm-2017-0322.
    Full Text Link to Item
  - Sumanasuriya, Semini, Aurelius Omlin, Andrew Armstrong, Gerhardt Attard, Kim N. Chi, Charlotte L. Bevan, Aki Shibakawa, et al. “Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer.” Eur Urol Oncol 1, no. 2 (June 2018): 151–59. https://doi.org/10.1016/j.euo.2018.02.009.
    Full Text Link to Item
  - Rathkopf, Dana E., Tomasz M. Beer, Yohann Loriot, Celestia S. Higano, Andrew J. Armstrong, Cora N. Sternberg, Johann S. de Bono, et al. “Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial.” Jama Oncol 4, no. 5 (May 1, 2018): 694–701. https://doi.org/10.1001/jamaoncol.2017.5808.
    Full Text Link to Item
  - Humeniuk, Michael S., Rajan T. Gupta, Patrick Healy, Megan McNamara, Sundhar Ramalingam, Michael Harrison, Daniel George, Tian Zhang, Yuan Wu, and Andrew J. Armstrong. “Platinum sensitivity in metastatic prostate cancer: does histology matter?” Prostate Cancer Prostatic Dis 21, no. 1 (April 2018): 92–99. https://doi.org/10.1038/s41391-017-0017-6.
    Full Text Link to Item
  - Austin, R Garland, Tony Jun Huang, Mengxi Wu, Andrew J. Armstrong, and Tian Zhang. “Clinical utility of non-EpCAM based circulating tumor cell assays.” Adv Drug Deliv Rev 125 (February 1, 2018): 132–42. https://doi.org/10.1016/j.addr.2018.01.013.
    Full Text Link to Item
  - Zhu, Jason, Andrew J. Armstrong, Terence W. Friedlander, Won Kim, Sumanta K. Pal, Daniel J. George, and Tian Zhang. “Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.” J Immunother Cancer 6, no. 1 (January 25, 2018): 4. https://doi.org/10.1186/s40425-018-0314-1.
    Full Text Open Access Copy Link to Item
  - Armstrong, A. J., E. S. Antonarakis, M. -. E. Taplin, W. K. Kelly, H. Beltran, K. Fizazi, W. L. Dahut, et al. “Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.” Ann Oncol 29, no. 1 (January 1, 2018): 23–25. https://doi.org/10.1093/annonc/mdx648.
    Full Text Link to Item
  - Taplin, Mary-Ellen, Andrew J. Armstrong, Ping Lin, Andrew Krivoshik, De Phung, Teresa Parli, Bertrand Tombal, and Tomasz M. Beer. “Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo.” J Urol 198, no. 6 (December 2017): 1324–32. https://doi.org/10.1016/j.juro.2017.07.071.
    Full Text Link to Item
  - Zhu, Jason, Matthew Tucker, Endi Wang, Joel S. Grossman, Andrew J. Armstrong, Daniel J. George, and Tian Zhang. “Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer.” Clin Genitourin Cancer 15, no. 6 (December 2017): e1137–41. https://doi.org/10.1016/j.clgc.2017.07.005.
    Full Text Open Access Copy Link to Item
  - Zhang, Tian, and Andrew J. Armstrong. “The Who, What, and How of Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer.” J Clin Oncol 35, no. 28 (October 1, 2017): 3175–77. https://doi.org/10.1200/JCO.2017.74.7931.
    Full Text Link to Item
  - Humeniuk, Michael S., Tian Zhang, and Andrew J. Armstrong. “Exploiting DNA damage without repair: The activity of platinum chemotherapy in BRCA-mutated prostate cancers.” Cancer 123, no. 18 (September 15, 2017): 3441–44. https://doi.org/10.1002/cncr.30806.
    Full Text Link to Item
  - Humeniuk, Michael S., and Andrew J. Armstrong. “RECISTing the Temptation to Prematurely Stop Nivolumab.” Eur Urol 72, no. 3 (September 2017): 377–78. https://doi.org/10.1016/j.eururo.2017.04.021.
    Full Text Link to Item
  - Armstrong, Andrew J., Fred Saad, De Phung, Carl Dmuchowski, Neal D. Shore, Karim Fizazi, Mohammad Hirmand, David Forer, Howard I. Scher, and Johann De Bono. “Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.” Cancer 123, no. 12 (June 15, 2017): 2303–11. https://doi.org/10.1002/cncr.30587.
    Full Text Link to Item
  - Bryce, A. H., J. J. Alumkal, A. Armstrong, C. S. Higano, P. Iversen, C. N. Sternberg, D. Rathkopf, et al. “Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL.” Prostate Cancer Prostatic Dis 20, no. 2 (June 2017): 221–27. https://doi.org/10.1038/pcan.2016.71.
    Full Text Link to Item
  - Ramalingam, Sundhar, Michael S. Humeniuk, Rachel Hu, Julia Rasmussen, Patrick Healy, Yuan Wu, Michael R. Harrison, Andrew J. Armstrong, Daniel J. George, and Tian Zhang. “Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer.” Urol Oncol 35, no. 6 (June 2017): 418–24. https://doi.org/10.1016/j.urolonc.2016.12.016.
    Full Text Link to Item
  - Ware, Kathryn E., Shivee Gilja, Shenghan Xu, Samantha Shetler, Mohit K. Jolly, Xueyang Wang, Suzanne Bartholf Dewitt, et al. “Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells.” J Vis Exp, no. 122 (April 7, 2017). https://doi.org/10.3791/55520.
    Full Text Link to Item
  - Sonpavde, Guru, and Andrew J. Armstrong. “Drug development in prostate cancer: time to embrace RECIST?” Lancet Oncol 18, no. 4 (April 2017): 419–21. https://doi.org/10.1016/S1470-2045(17)30149-3.
    Full Text Link to Item
  - Armstrong, Andrew J. “Prognostic and predictive biomarkers in metastatic castration-resistant prostate cancer.” Clin Adv Hematol Oncol 15, no. 3 (March 2017): 184–88.
    Link to Item
  - Gupta, Santosh, Jing Li, Gabor Kemeny, Rhonda L. Bitting, Joshua Beaver, Jason A. Somarelli, Kathryn E. Ware, Simon Gregory, and Andrew J. Armstrong. “Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer.” Clin Cancer Res 23, no. 5 (March 1, 2017): 1346–57. https://doi.org/10.1158/1078-0432.CCR-16-1211.
    Full Text Link to Item
  - Penson, David F., Andrew J. Armstrong, Raoul Concepcion, Neeraj Agarwal, Carl Olsson, Lawrence Karsh, Curtis Dunshee, et al. “Reply to M.A.N. Şendur et al and J. Michels.” J Clin Oncol 35, no. 1 (January 2017): 123. https://doi.org/10.1200/JCO.2016.69.9371.
    Full Text Link to Item
  - Ramalingam, Sundhar, Adva Eisenberg, Wen Chi Foo, Jennifer Freedman, Andrew J. Armstrong, Larry G. Moss, and Michael R. Harrison. “Treatment-related neuroendocrine prostate cancer resulting in Cushing's syndrome.” Int J Urol 23, no. 12 (December 2016): 1038–41. https://doi.org/10.1111/iju.13225.
    Full Text Link to Item
  - Armstrong, Andrew J. “Predictive medicine: Using circulating biomarkers to guide management of patients with genitourinary cancers.” Urol Oncol 34, no. 11 (November 2016): 488–89. https://doi.org/10.1016/j.urolonc.2016.09.009.
    Full Text Link to Item
  - Beltran, H., D. Danila, B. Montgomery, R. Szmulewitz, U. Vaishampayan, A. Armstrong, M. Stein, et al. “A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC).” Annals of Oncology 27 (October 1, 2016): vi565. https://doi.org/10.1093/annonc/mdw435.21.
    Full Text
  - Stenzl, A., A. Krivoshik, B. Baron, M. Hirmand, and A. Armstrong. “Efficacy and safety of enzalutamide plus androgen deprivation therapy vs placebo plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: the ongoing ARCHES trial.” Annals of Oncology 27 (October 1, 2016): vi262. https://doi.org/10.1093/annonc/mdw372.51.
    Full Text
  - Evans, Christopher P., Celestia S. Higano, Thomas Keane, Gerald Andriole, Fred Saad, Peter Iversen, Kurt Miller, et al. “The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.” Eur Urol 70, no. 4 (October 2016): 675–83. https://doi.org/10.1016/j.eururo.2016.03.017.
    Full Text Link to Item
  - Somarelli, Jason A., Samantha Shetler, Mohit K. Jolly, Xueyang Wang, Suzanne Bartholf Dewitt, Alexander J. Hish, Shivee Gilja, et al. “Mesenchymal-Epithelial Transition in Sarcomas Is Controlled by the Combinatorial Expression of MicroRNA 200s and GRHL2.” Mol Cell Biol 36, no. 19 (October 1, 2016): 2503–13. https://doi.org/10.1128/MCB.00373-16.
    Full Text Open Access Copy Link to Item
  - Shields Iv, C Wyatt, Jeffrey L. Wang, Korine A. Ohiri, Eric D. Essoyan, Benjamin B. Yellen, Andrew J. Armstrong, and Gabriel P. López. “Magnetic separation of acoustically focused cancer cells from blood for magnetographic templating and analysis.” Lab Chip 16, no. 19 (September 21, 2016): 3833–44. https://doi.org/10.1039/c6lc00719h.
    Full Text Link to Item
  - Antonarakis, E. S., A. J. Armstrong, S. M. Dehm, and J. Luo. “Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.” Prostate Cancer Prostatic Dis 19, no. 3 (September 2016): 231–41. https://doi.org/10.1038/pcan.2016.17.
    Full Text Link to Item
  - Somarelli, J. A., D. Schaeffer, M. S. Marengo, T. Bepler, D. Rouse, K. E. Ware, A. J. Hish, et al. “Distinct routes to metastasis: plasticity-dependent and plasticity-independent pathways.” Oncogene 35, no. 33 (August 18, 2016): 4302–11. https://doi.org/10.1038/onc.2015.497.
    Full Text Open Access Copy Link to Item
  - Ware, Kathryn E., Jason A. Somarelli, Daneen Schaeffer, Jing Li, Tian Zhang, Sally Park, Steven R. Patierno, et al. “Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer.” Oncotarget 7, no. 31 (August 2, 2016): 50507–21. https://doi.org/10.18632/oncotarget.10476.
    Full Text Open Access Copy Link to Item
  - Penson, David F., Andrew J. Armstrong, Raoul Concepcion, Neeraj Agarwal, Carl Olsson, Lawrence Karsh, Curtis Dunshee, et al. “Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.” J Clin Oncol 34, no. 18 (June 20, 2016): 2098–2106. https://doi.org/10.1200/JCO.2015.64.9285.
    Full Text Link to Item
  - Sonpavde, Guru, Gregory R. Pond, Arnoud J. Templeton, Abderrahim Fandi, Bertrand Tombal, Mark Rosenthal, Andrew J. Armstrong, and Daniel P. Petrylak. “Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel.” Eur Urol 69, no. 6 (June 2016): 980–83. https://doi.org/10.1016/j.eururo.2015.10.008.
    Full Text Link to Item
  - Zhang, Tian, Rengasamy Boominathan, Brad Foulk, Chandra Rao, Gabor Kemeny, John H. Strickler, James L. Abbruzzese, et al. “Development of a Novel c-MET-Based CTC Detection Platform.” Mol Cancer Res 14, no. 6 (June 2016): 539–47. https://doi.org/10.1158/1541-7786.MCR-16-0011.
    Full Text Open Access Copy Link to Item
  - Halabi, Susan, William Kevin Kelly, Hua Ma, Haojin Zhou, Nicole C. Solomon, Karim Fizazi, Catherine M. Tangen, et al. “Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.” J Clin Oncol 34, no. 14 (May 10, 2016): 1652–59. https://doi.org/10.1200/JCO.2015.65.7270.
    Full Text Link to Item
  - Scher, Howard I., Michael J. Morris, Walter M. Stadler, Celestia Higano, Ethan Basch, Karim Fizazi, Emmanuel S. Antonarakis, et al. “Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.” J Clin Oncol 34, no. 12 (April 20, 2016): 1402–18. https://doi.org/10.1200/JCO.2015.64.2702.
    Full Text Link to Item
  - Armstrong, A. J., P. Healy, S. Halabi, R. Vollmer, A. Lark, G. Kemeny, K. Ware, and S. J. Freedland. “Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer.” Prostate Cancer Prostatic Dis 19, no. 1 (March 2016): 40–45. https://doi.org/10.1038/pcan.2015.46.
    Full Text Open Access Copy Link to Item
  - Armstrong, Andrew J., Susan Halabi, Tim Eisen, Samuel Broderick, Walter M. Stadler, Robert J. Jones, Jorge A. Garcia, et al. “Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.” Lancet Oncol 17, no. 3 (March 2016): 378–88. https://doi.org/10.1016/S1470-2045(15)00515-X.
    Full Text Link to Item
  - Graff, J. N., G. Baciarello, A. J. Armstrong, C. S. Higano, P. Iversen, T. W. Flaig, D. Forer, et al. “Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL.” Ann Oncol 27, no. 2 (February 2016): 286–94. https://doi.org/10.1093/annonc/mdv542.
    Full Text Link to Item
  - Mehta, Amit R., and Andrew J. Armstrong. “Tasquinimod in the treatment of castrate-resistant prostate cancer - current status and future prospects.” Ther Adv Urol 8, no. 1 (February 2016): 9–18. https://doi.org/10.1177/1756287215603558.
    Full Text Link to Item
  - Tay, Kae Jack, Judd W. Moul, and Andrew J. Armstrong. “Management of Prostate Cancer in the Elderly.” Clin Geriatr Med 32, no. 1 (February 2016): 113–32. https://doi.org/10.1016/j.cger.2015.08.001.
    Full Text Link to Item
  - Mohler, James L., Andrew J. Armstrong, Robert R. Bahnson, Anthony Victor D’Amico, Brian J. Davis, James A. Eastham, Charles A. Enke, et al. “Prostate Cancer, Version 1.2016.” J Natl Compr Canc Netw 14, no. 1 (January 2016): 19–30. https://doi.org/10.6004/jnccn.2016.0004.
    Full Text Link to Item
  - Zhang, Tian, and Andrew J. Armstrong. “Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer.” Curr Oncol Rep 18, no. 1 (January 2016): 3. https://doi.org/10.1007/s11912-015-0490-9.
    Full Text Link to Item
  - Zhang, Tian, and Andrew J. Armstrong. “Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch.” Clin Cancer Res 21, no. 20 (October 15, 2015): 4505–7. https://doi.org/10.1158/1078-0432.CCR-15-1613.
    Full Text Open Access Copy Link to Item
  - Hussain, Maha, Dana Rathkopf, Glenn Liu, Andrew Armstrong, Wm Kevin Kelly, Anna Ferrari, John Hainsworth, et al. “A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.” Eur J Cancer 51, no. 13 (September 2015): 1714–24. https://doi.org/10.1016/j.ejca.2015.05.019.
    Full Text Link to Item
  - Kanesvaran, Ravindran, Kevin Watt, James D. Turnbull, Andrew J. Armstrong, Michael Cohen Wolkowiez, and Daniel J. George. “A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma.” Clin Genitourin Cancer 13, no. 4 (August 2015): 319–27. https://doi.org/10.1016/j.clgc.2014.12.011.
    Full Text Link to Item
  - Zhang, Tian, Mallika S. Dhawan, Patrick Healy, Daniel J. George, Michael R. Harrison, Jorge Oldan, Bennett Chin, and Andrew J. Armstrong. “Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.” Clin Genitourin Cancer 13, no. 4 (August 2015): 392–99. https://doi.org/10.1016/j.clgc.2015.01.004.
    Full Text Link to Item
  - Armstrong, Andrew J. “Docetaxel for advanced prostate cancer: how early to start?” Lancet Oncol 16, no. 7 (July 2015): 741–42. https://doi.org/10.1016/S1470-2045(15)00012-1.
    Full Text Link to Item
  - Sonpavde, Guru, Christopher G. Wang, Matthew D. Galsky, William K. Oh, and Andrew J. Armstrong. “Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).” Bju Int 116, no. 1 (July 2015): 17–29. https://doi.org/10.1111/bju.12867.
    Full Text Link to Item
  - Somarelli, Jason A., Mary-Keara Boss, Jonathan I. Epstein, Andrew J. Armstrong, and Mariano A. Garcia-Blanco. “Carcinosarcomas: tumors in transition?” Histol Histopathol 30, no. 6 (June 2015): 673–87. https://doi.org/10.14670/HH-30.673.
    Full Text Link to Item
  - Stover, J. T., R. A. Moore, K. Davis, M. R. Harrison, and A. J. Armstrong. “Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer.” Prostate Cancer Prostatic Dis 18, no. 2 (June 2015): 161–66. https://doi.org/10.1038/pcan.2015.7.
    Full Text Link to Item
  - Davis, Kristen, Sarah Wood, Emily Dill, Yuri Fesko, Rhonda L. Bitting, Michael R. Harrison, Andrew J. Armstrong, Judd W. Moul, and Daniel J. George. “Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution.” Clin J Oncol Nurs 19, no. 3 (June 2015): 297–303. https://doi.org/10.1188/15.CJON.297-303.
    Full Text Link to Item
  - Armstrong, Andrew J. “New treatment options in castration-resistant prostate cancer.” J Natl Compr Canc Netw 13, no. 5 Suppl (May 2015): 690–93. https://doi.org/10.6004/jnccn.2015.0205.
    Full Text Link to Item
  - Li, Jing, and Andrew J. Armstrong. “Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.” Clin Adv Hematol Oncol 13, no. 5 (May 2015): 293–98.
    Link to Item
  - Armstrong, Andrew J., and Susan Halabi. “Making progress on progression in metastatic prostate cancer.” J Clin Oncol 33, no. 12 (April 20, 2015): 1322–24. https://doi.org/10.1200/JCO.2014.59.4283.
    Full Text Link to Item
  - Harrison, Michael R., and Andrew J. Armstrong. “Burden of disease matters when it comes to systemic therapy for prostate cancer.” Eur Urol 67, no. 3 (March 2015): 448–50. https://doi.org/10.1016/j.eururo.2014.02.032.
    Full Text Link to Item
  - Bitting, Rhonda L., Patrick Healy, Susan Halabi, Daniel J. George, Michael Goodin, and Andrew J. Armstrong. “Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.” Urol Oncol 33, no. 3 (March 2015): 110.e1-110.e9. https://doi.org/10.1016/j.urolonc.2014.09.002.
    Full Text Link to Item
  - Zhang, Tian, Jason Zhu, Daniel J. George, and Andrew J. Armstrong. “Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.” Expert Opin Pharmacother 16, no. 4 (March 2015): 473–85. https://doi.org/10.1517/14656566.2015.995090.
    Full Text Link to Item
  - Shuch, Brian, Ali Amin, Andrew J. Armstrong, John N. Eble, Vincenzo Ficarra, Antonio Lopez-Beltran, Guido Martignoni, Brian I. Rini, and Alexander Kutikov. “Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity.” Eur Urol 67, no. 1 (January 2015): 85–97. https://doi.org/10.1016/j.eururo.2014.04.029.
    Full Text Link to Item
  - Li, Jing, Simon G. Gregory, Mariano A. Garcia-Blanco, and Andrew J. Armstrong. “Using circulating tumor cells to inform on prostate cancer biology and clinical utility.” Crit Rev Clin Lab Sci 52, no. 4 (2015): 191–210. https://doi.org/10.3109/10408363.2015.1023430.
    Full Text Link to Item
  - Sonpavde, Guru, Gregory R. Pond, Andrew J. Armstrong, Matthew D. Galsky, Lance Leopold, Brian A. Wood, Shaw-Ling Wang, et al. “Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.” Bju Int 114, no. 6b (December 2014): E25–31. https://doi.org/10.1111/bju.12589.
    Full Text Link to Item
  - Stewart, Suzanne B., Judd W. Moul, Thomas J. Polascik, Bridget F. Koontz, Cary N. Robertson, Stephen J. Freedland, Daniel J. George, W Robert Lee, Andrew J. Armstrong, and Lionel L. Bañez. “Does the multidisciplinary approach improve oncological outcomes in men undergoing surgical treatment for prostate cancer?” Int J Urol 21, no. 12 (December 2014): 1215–19. https://doi.org/10.1111/iju.12561.
    Full Text Link to Item
  - Armstrong, Andrew J., Reza Kaboteh, Michael A. Carducci, Jan-Erik Damber, Walter M. Stadler, Mats Hansen, Lars Edenbrandt, et al. “Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).” Urol Oncol 32, no. 8 (November 2014): 1308–16. https://doi.org/10.1016/j.urolonc.2014.08.006.
    Full Text Link to Item
  - Armstrong, A. J. “In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet.” Oncology (Williston Park, N.Y.) 28, no. 10 (October 1, 2014): 883.
  - Armstrong, Andrew J. “In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet.” Oncology (Williston Park) 28, no. 10 (October 2014): 881–83.
    Link to Item
  - Sonpavde, Guru, Gregory R. Pond, Andrew J. Armstrong, Stephen J. Clarke, Janette L. Vardy, Arnoud J. Templeton, Shaw-Ling Wang, et al. “Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.” Clin Genitourin Cancer 12, no. 5 (October 2014): 317–24. https://doi.org/10.1016/j.clgc.2014.03.005.
    Full Text Link to Item
  - Bitting, Rhonda L., Daneen Schaeffer, Jason A. Somarelli, Mariano A. Garcia-Blanco, and Andrew J. Armstrong. “The role of epithelial plasticity in prostate cancer dissemination and treatment resistance.” Cancer Metastasis Rev 33, no. 2–3 (September 2014): 441–68. https://doi.org/10.1007/s10555-013-9483-z.
    Full Text Link to Item
  - Halabi, S., H. Zhou, E. J. Small, N. C. Solomon, A. J. Armstrong, L. Shen, S. Oudard, O. Sartor, and J. S. de Bono. “795PA PROGNOSTIC MODEL FOR PREDICTING RADIOGRAPHIC PROGRESSION- FREE SURVIVAL (RPFS) IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER MEN TREATED WITH SECOND-LINE CHEMOTHERAPY.” Ann Oncol 25, no. suppl_4 (September 1, 2014): iv276. https://doi.org/10.1093/annonc/mdu336.43.
    Full Text Link to Item
  - Bitting, Rhonda L., Patrick Healy, Patricia A. Creel, James Turnbull, Karla Morris, Sarah Yenser Wood, Herbert I. Hurwitz, et al. “A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.” Clin Genitourin Cancer 12, no. 4 (August 2014): 241–50. https://doi.org/10.1016/j.clgc.2013.11.020.
    Full Text Link to Item
  - Ware, Kathryn E., Mariano A. Garcia-Blanco, Andrew J. Armstrong, and Scott M. Dehm. “Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer.” Endocr Relat Cancer 21, no. 4 (August 2014): T87–103. https://doi.org/10.1530/ERC-13-0470.
    Full Text Link to Item
  - Beer, Tomasz M., Andrew J. Armstrong, Dana E. Rathkopf, Yohann Loriot, Cora N. Sternberg, Celestia S. Higano, Peter Iversen, et al. “Enzalutamide in metastatic prostate cancer before chemotherapy.” N Engl J Med 371, no. 5 (July 31, 2014): 424–33. https://doi.org/10.1056/NEJMoa1405095.
    Full Text Link to Item
  - Mohler, James L., Philip W. Kantoff, Andrew J. Armstrong, Robert R. Bahnson, Michael Cohen, Anthony Victor D’Amico, James A. Eastham, et al. “Prostate cancer, version 2.2014.” J Natl Compr Canc Netw 12, no. 5 (May 2014): 686–718. https://doi.org/10.6004/jnccn.2014.0072.
    Full Text Link to Item
  - Aggarwal, Rahul, Tian Zhang, Eric J. Small, and Andrew J. Armstrong. “Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes.” J Natl Compr Canc Netw 12, no. 5 (May 2014): 719–26. https://doi.org/10.6004/jnccn.2014.0073.
    Full Text Link to Item
  - Younis, Islam R., Daniel J. George, Terence J. McManus, Herbert Hurwitz, Patricia Creel, Andrew J. Armstrong, Jing Jie Yu, et al. “Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer.” Cancer Chemother Pharmacol 73, no. 5 (May 2014): 991–97. https://doi.org/10.1007/s00280-014-2432-x.
    Full Text Link to Item
  - Armstrong, A. J. “Biomarkers in castration-resistant prostate cancer.” Clinical Advances in Hematology and Oncology 12, no. 2 (February 1, 2014): 115–18.
  - Armstrong, Andrew J. “Biomarkers in castration-resistant prostate cancer.” Clin Adv Hematol Oncol 12, no. 2 (February 2014): 115–18.
    Link to Item
  - Armstrong, Andrew J. “New treatments for men with castration-resistant prostate cancer: can we move from small steps to giant leaps?” Eur Urol 65, no. 2 (February 2014): 300–302. https://doi.org/10.1016/j.eururo.2013.08.059.
    Full Text Link to Item
  - Pond, Gregory R., Guru Sonpavde, Ronald de Wit, Mario A. Eisenberger, Ian F. Tannock, and Andrew J. Armstrong. “The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer.” Eur Urol 65, no. 1 (January 2014): 3–6. https://doi.org/10.1016/j.eururo.2013.09.024.
    Full Text Link to Item
  - Armstrong, A. J., M. Häggman, W. M. Stadler, J. R. Gingrich, V. Assikis, J. Polikoff, J. E. Damber, et al. “Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer.” Clin Cancer Res 19, no. 24 (December 15, 2013): 6891–6901. https://doi.org/10.1158/1078-0432.CCR-13-1581.
    Full Text Link to Item
  - Stoyanova, Tanya, Aaron R. Cooper, Justin M. Drake, Xian Liu, Andrew J. Armstrong, Kenneth J. Pienta, Hong Zhang, et al. “Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells.” Proc Natl Acad Sci U S A 110, no. 50 (December 10, 2013): 20111–16. https://doi.org/10.1073/pnas.1320565110.
    Full Text Link to Item
  - Araujo, John C., Géralyn C. Trudel, Fred Saad, Andrew J. Armstrong, Evan Y. Yu, Joaquim Bellmunt, George Wilding, et al. “Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.” Lancet Oncol 14, no. 13 (December 2013): 1307–16. https://doi.org/10.1016/S1470-2045(13)70479-0.
    Full Text Link to Item
  - Bitting, Rhonda L., Rengasamy Boominathan, Chandra Rao, Gabor Kemeny, Brad Foulk, Mariano A. Garcia-Blanco, Mark Connelly, and Andrew J. Armstrong. “Development of a method to isolate circulating tumor cells using mesenchymal-based capture.” Methods 64, no. 2 (December 1, 2013): 129–36. https://doi.org/10.1016/j.ymeth.2013.06.034.
    Full Text Link to Item
  - Mohler, James L., Philip W. Kantoff, Andrew J. Armstrong, Robert R. Bahnson, Michael Cohen, Anthony Victor D’Amico, James A. Eastham, et al. “Prostate cancer, version 1.2014.” J Natl Compr Canc Netw 11, no. 12 (December 1, 2013): 1471–79. https://doi.org/10.6004/jnccn.2013.0174.
    Full Text Link to Item
  - Schweizer, M. T., J. Lin, A. Blackford, A. Bardia, S. King, A. J. Armstrong, M. A. Rudek, S. Yegnasubramanian, and M. A. Carducci. “Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer.” Prostate Cancer and Prostatic Diseases 16, no. 4 (December 1, 2013): 357–61. https://doi.org/10.1038/pcan.2013.28.
    Full Text
  - Schweizer, M. T., J. Lin, A. Blackford, A. Bardia, S. King, A. J. Armstrong, M. A. Rudek, S. Yegnasubramanian, and M. A. Carducci. “Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer.” Prostate Cancer Prostatic Dis 16, no. 4 (December 2013): 357–61. https://doi.org/10.1038/pcan.2013.28.
    Full Text Link to Item
  - Armstrong, Andrew J., Tong Shen, Susan Halabi, Gabor Kemeny, Rhonda L. Bitting, Patricia Kartcheske, Elizabeth Embree, et al. “A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.” Clin Genitourin Cancer 11, no. 4 (December 2013): 397–406. https://doi.org/10.1016/j.clgc.2013.05.007.
    Full Text Link to Item
  - Halabi, Susan, Chen-Yen Lin, Eric J. Small, Andrew J. Armstrong, Ellen B. Kaplan, Daniel Petrylak, Cora N. Sternberg, et al. “Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.” J Natl Cancer Inst 105, no. 22 (November 20, 2013): 1729–37. https://doi.org/10.1093/jnci/djt280.
    Full Text Link to Item
  - Pond, Gregory R., Andrew J. Armstrong, Matthew D. Galsky, Brian A. Wood, Lance Leopold, and Guru Sonpavde. “Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.” Urol Oncol 31, no. 8 (November 2013): 1457–63. https://doi.org/10.1016/j.urolonc.2012.02.008.
    Full Text Link to Item
  - Halabi, Susan, Andrew J. Armstrong, Oliver Sartor, Johann de Bono, Ellen Kaplan, Chen-Yen Lin, Nicole C. Solomon, and Eric J. Small. “Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy.” J Clin Oncol 31, no. 31 (November 1, 2013): 3944–50. https://doi.org/10.1200/JCO.2013.50.3201.
    Full Text Link to Item
  - Zhang, Tian, and Andrew J. Armstrong. “Clinical phenotypes of castration-resistant prostate cancer.” Clin Adv Hematol Oncol 11, no. 11 (November 2013): 707–18.
    Link to Item
  - Peppercorn, Jeffrey, Andrew Armstrong, David W. Zaas, and Daniel George. “Rationing in urologic oncology: lessons from sipuleucel-T for advanced prostate cancer.” Urol Oncol 31, no. 7 (October 2013): 1079–84. https://doi.org/10.1016/j.urolonc.2011.12.022.
    Full Text Link to Item
  - George, Daniel J., Andrew J. Armstrong, and Michael R. Harrison. “Highlights in advanced prostate cancer from the 2013 American Urological Association Annual Meeting and the 2013 American Society of Clinical Oncology Annual Meeting: commentary.” Clin Adv Hematol Oncol 11 Suppl 14, no. 9 (September 2013): 16–22.
    Link to Item
  - Noonan, K. L., S. North, R. L. Bitting, A. J. Armstrong, S. L. Ellard, and K. N. Chi. “Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide.” Ann Oncol 24, no. 7 (July 2013): 1802–7. https://doi.org/10.1093/annonc/mdt138.
    Full Text Link to Item
  - Bitting, Rhonda L., and Andrew J. Armstrong. “Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.” Endocr Relat Cancer 20, no. 3 (June 2013): R83–99. https://doi.org/10.1530/ERC-12-0394.
    Full Text Link to Item
  - Turnbull, James D., Julien Cobert, Tracy Jaffe, Michael R. Harrison, Daniel J. George, and Andrew J. Armstrong. “Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.” Clin Genitourin Cancer 11, no. 1 (March 2013): 45–50. https://doi.org/10.1016/j.clgc.2012.06.001.
    Full Text Link to Item
  - Armstrong, Andrew J., Daniel J. George, and Susan Halabi. “Reply to M A Khattak et al.” J Clin Oncol 31, no. 7 (March 1, 2013): 972–73. https://doi.org/10.1200/JCO.2012.47.7224.
    Full Text Link to Item
  - Clarke, J. M., and A. J. Armstrong. “Novel therapies for the treatment of advanced prostate cancer.” Curr Treat Options Oncol 14, no. 1 (March 2013): 109–26. https://doi.org/10.1007/s11864-012-0222-4.
    Full Text Link to Item
  - Bardia, A., A. L. Blackford, J. Lin, A. J. Armstrong, S. King, M. A. Rudek, S. T. Yegnasubramanian, and M. A. Carducci. “A prostate cancer clinical trials consortium trial of disulfiram (D) in men with nonmetastatic recurrent prostate cancer (PCa).” J Clin Oncol 31, no. 6_suppl (February 20, 2013): 219. https://doi.org/10.1200/jco.2013.31.6_suppl.219.
    Full Text Link to Item
  - Fizazi, K., F. Saad, K. N. Chi, M. E. Taplin, C. N. Sternberg, A. J. Armstrong, M. Hirmand, D. Forer, and J. S. De Bono. “Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor.” J Clin Oncol 31, no. 6_suppl (February 20, 2013): 6. https://doi.org/10.1200/jco.2013.31.6_suppl.6.
    Full Text Link to Item
  - Lin, C. Y., E. J. Small, A. J. Armstrong, E. B. Kaplan, D. P. Petrylak, C. N. Sternberg, L. Shen, S. Oudard, J. S. De Bono, and A. O. Sartor. “A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed.” J Clin Oncol 31, no. 6_suppl (February 20, 2013): 24. https://doi.org/10.1200/jco.2013.31.6_suppl.24.
    Full Text Link to Item
  - Trudel, G. C., F. Saad, A. J. Armstrong, E. Y. Yu, J. Bellmunt, G. Wilding, J. McCaffrey, et al. “Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial.” J Clin Oncol 31, no. 6_suppl (February 20, 2013): LBA8. https://doi.org/10.1200/jco.2013.31.6_suppl.lba8.
    Full Text Link to Item
  - Saylor, Philip J., Andrew J. Armstrong, Karim Fizazi, Stephen Freedland, Fred Saad, Matthew R. Smith, Bertrand Tombal, and Kenneth Pienta. “New and emerging therapies for bone metastases in genitourinary cancers.” Eur Urol 63, no. 2 (February 2013): 309–20. https://doi.org/10.1016/j.eururo.2012.10.007.
    Full Text Link to Item
  - Harrison, Michael R., Terence Z. Wong, Andrew J. Armstrong, and Daniel J. George. “Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease.” Cancer Manag Res 5 (2013): 1–14. https://doi.org/10.2147/CMAR.S25537.
    Full Text Link to Item
  - Whang, Young E., Andrew J. Armstrong, W Kimryn Rathmell, Paul A. Godley, William Y. Kim, Raj S. Pruthi, Eric M. Wallen, et al. “A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer.” Urol Oncol 31, no. 1 (January 2013): 82–86. https://doi.org/10.1016/j.urolonc.2010.09.018.
    Full Text Link to Item
  - Bitting, Rhonda L., and Andrew J. Armstrong. “Potential predictive biomarkers for individualizing treatment for men with castration-resistant prostate cancer.” Cancer J 19, no. 1 (2013): 25–33. https://doi.org/10.1097/PPO.0b013e31827e0b9c.
    Full Text Link to Item
  - Khazanie, P., and C. B. Granger. “Commentary.” Annals of Internal Medicine 158, no. 4 (2013).
  - Pond, Gregory R., Andrew J. Armstrong, Brian A. Wood, Lance Leopold, Matthew D. Galsky, and Guru Sonpavde. “Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy.” Bju Int 110, no. 11 Pt B (December 2012): E461–68. https://doi.org/10.1111/j.1464-410X.2012.11148.x.
    Full Text Link to Item
  - Scher, Howard I., Karim Fizazi, Fred Saad, Mary-Ellen Taplin, Cora N. Sternberg, Kurt Miller, Ronald de Wit, et al. “Increased survival with enzalutamide in prostate cancer after chemotherapy.” N Engl J Med 367, no. 13 (September 27, 2012): 1187–97. https://doi.org/10.1056/NEJMoa1207506.
    Full Text Link to Item
  - Armstrong, Andrew J., Daniel J. George, and Susan Halabi. “Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.” J Clin Oncol 30, no. 27 (September 20, 2012): 3402–7. https://doi.org/10.1200/JCO.2011.40.9631.
    Full Text Link to Item
  - Sonpavde, Guru, Gregory R. Pond, William R. Berry, Ronald de Wit, Andrew J. Armstrong, Mario A. Eisenberger, and Ian F. Tannock. “Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy.” Urol Oncol 30, no. 5 (September 2012): 607–13. https://doi.org/10.1016/j.urolonc.2010.07.002.
    Full Text Link to Item
  - Mohler, James L., Andrew J. Armstrong, Robert R. Bahnson, Barry Boston, J Erik Busby, Anthony Victor D’Amico, James A. Eastham, et al. “Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines.” J Natl Compr Canc Netw 10, no. 9 (September 2012): 1081–87. https://doi.org/10.6004/jnccn.2012.0114.
    Full Text Link to Item
  - Armstrong, A. J. “Where does abiraterone fit into the metastatic prostate cancer treatment algorithm?” Community Oncology 9, no. 8 (August 1, 2012): 238–39. https://doi.org/10.1016/j.cmonc.2012.07.006.
    Full Text
  - Sonpavde, Guru, and Andrew J. Armstrong. “Objective evaluation of bone metastases in prostate cancer: to what end?” Eur Urol 62, no. 1 (July 2012): 85–87. https://doi.org/10.1016/j.eururo.2012.02.021.
    Full Text Link to Item
  - Armstrong, Andrew J. “The STAMPEDE trial and celecoxib: how to adapt?” Lancet Oncol 13, no. 5 (May 2012): 443–45. https://doi.org/10.1016/S1470-2045(12)70111-0.
    Full Text Link to Item
  - Sandilos, Joanna K., Yu-Hsin Chiu, Faraaz B. Chekeni, Allison J. Armstrong, Scott F. Walk, Kodi S. Ravichandran, and Douglas A. Bayliss. “Pannexin 1, an ATP release channel, is activated by caspase cleavage of its pore-associated C-terminal autoinhibitory region.” J Biol Chem 287, no. 14 (March 30, 2012): 11303–11. https://doi.org/10.1074/jbc.M111.323378.
    Full Text Link to Item
  - Armstrong, Andrew J., Mario A. Eisenberger, Susan Halabi, Stephane Oudard, David M. Nanus, Daniel P. Petrylak, A Oliver Sartor, and Howard I. Scher. “Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.” Eur Urol 61, no. 3 (March 2012): 549–59. https://doi.org/10.1016/j.eururo.2011.11.009.
    Full Text Link to Item
  - Armstrong, A. J., J. D. Turnbull, J. Cobert, T. Jaffe, M. R. Harrison, and D. J. George. “Activity of single-agent bevacizumab (B) in patients with metastatic renal cell carcinoma (RCC) previously treated with VEGF- and mTOR-based therapies.” J Clin Oncol 30, no. 5_suppl (February 10, 2012): 435. https://doi.org/10.1200/jco.2012.30.5_suppl.435.
    Full Text Link to Item
  - Armstrong, A. J., J. D. Turnbull, J. Cobert, T. Jaffe, M. R. Harrison, and D. J. George. “Activity of single-agent bevacizumab (B) in patients with metastatic renal cell carcinoma (RCC) previously treated with VEGF- and mTOR-based therapies.” J Clin Oncol 30, no. 5_suppl (February 10, 2012): 435.
    Link to Item
  - Hussain, M., D. E. Rathkopf, G. Liu, A. J. Armstrong, W. K. Kelly, A. C. Ferrari, J. D. Hainsworth, L. Yang, J. D. Schwartz, and C. S. Higano. “A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy.” J Clin Oncol 30, no. 5_suppl (February 10, 2012): 97.
    Link to Item
  - Hussain, M., D. E. Rathkopf, G. Liu, A. J. Armstrong, W. K. Kelly, A. C. Ferrari, J. D. Hainsworth, L. Yang, J. D. Schwartz, and C. S. Higano. “A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy.” J Clin Oncol 30, no. 5_suppl (February 10, 2012): 97. https://doi.org/10.1200/jco.2012.30.5_suppl.97.
    Full Text Link to Item
  - Hussain, Maha, Dana E. Rathkopf, Glenn Liu, Andrew J. Armstrong, William Kevin Kelly, Anna C. Ferrari, John D. Hainsworth, Ling Yang, Jonathan D. Schwartz, and Celestia S. Higano. “A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy.” Journal of Clinical Oncology 30, no. 5 (February 10, 2012). https://doi.org/10.1200/jco.2012.30.5_suppl.97.
    Full Text Link to Item
  - Pond, G. R., A. J. Armstrong, B. A. Wood, L. H. Leopold, M. D. Galsky, and G. Sonpavde. “Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC).” J Clin Oncol 30, no. 5_suppl (February 10, 2012): 204.
    Link to Item
  - Pond, G. R., A. J. Armstrong, B. A. Wood, L. H. Leopold, M. D. Galsky, and G. Sonpavde. “Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC).” J Clin Oncol 30, no. 5_suppl (February 10, 2012): 204. https://doi.org/10.1200/jco.2012.30.5_suppl.204.
    Full Text Link to Item
  - Pond, Gregory Russell, Andrew J. Armstrong, Brian A. Wood, Lance Howard Leopold, Matt D. Galsky, and Guru Sonpavde. “Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC).” Journal of Clinical Oncology 30, no. 5 (February 10, 2012). https://doi.org/10.1200/jco.2012.30.5_suppl.204.
    Full Text Link to Item
  - Armstrong, A. J., J. R. Gingrich, M. Haggman, W. M. Stadler, J. E. Damber, L. Belkoff, R. Clark, et al. “Long term safety and efficacy in a randomized multicenter international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer.” European Urology Supplements 11, no. 1 (February 1, 2012): E126-U515.
    Link to Item
  - Pond, Gregory R., Andrew J. Armstrong, Brian A. Wood, Melissa Brookes, Lance Leopold, William R. Berry, Ronald de Wit, Mario A. Eisenberger, Ian F. Tannock, and Guru Sonpavde. “Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer.” Eur Urol 61, no. 2 (February 2012): 363–69. https://doi.org/10.1016/j.eururo.2011.06.034.
    Full Text Link to Item
  - Sonpavde, G., G. R. Pond, and A. J. Armstrong. “Reply to YiJun Shen and DingWei Ye's letter to the Editor re: Gregory R. Pond, Andrew J. Armstrong, Brian A. Wood, et al. Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur Urol 2012;61:363-9.” European Urology 61, no. 2 (February 1, 2012). https://doi.org/10.1016/j.eururo.2011.07.055.
    Full Text
  - Armstrong, A. J., J. W. Moul, and D. J. George. “What to order from the prostate cancer treatment menu?” Oncology (Williston Park, N.Y.) 26, no. 1 (January 1, 2012).
  - Bitting, Rhonda L., and Andrew J. Armstrong. “Prognostic, predictive, and surrogate factors for individualizing treatment for men with castration-resistant prostate cancer.” Am Soc Clin Oncol Educ Book, 2012, 292–97. https://doi.org/10.14694/EdBook_AM.2012.32.24.
    Full Text Link to Item
  - Stewart, Suzanne Biehn, Lionel L. Bañez, Cary N. Robertson, Stephen J. Freedland, Thomas J. Polascik, Donghua Xie, Bridget F. Koontz, et al. “Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center.” J Urol 187, no. 1 (January 2012): 103–8. https://doi.org/10.1016/j.juro.2011.09.040.
    Full Text Link to Item
  - Araujo, John C., Paul Mathew, Andrew J. Armstrong, Edward L. Braud, Edwin Posadas, Mathew Lonberg, Gary E. Gallick, et al. “Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.” Cancer 118, no. 1 (January 1, 2012): 63–71. https://doi.org/10.1002/cncr.26204.
    Full Text Link to Item
  - Armstrong, A. J. “Clinical update: Epithelial-mesenchymal transition in cancer progression.” Clinical Advances in Hematology and Oncology 9, no. 12 (December 1, 2011): 941–43.
  - Armstrong, Andrew J. “Epithelial-mesenchymal transition in cancer progression.” Clin Adv Hematol Oncol 9, no. 12 (December 2011): 941–43.
    Link to Item
  - Armstrong, Andrew J., Anna C. Ferrari, and David I. Quinn. “The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer.” Clin Adv Hematol Oncol 9, no. 12 Suppl 28 (December 2011): 1–14.
    Link to Item
  - Pili, Roberto, Michael Häggman, Walter M. Stadler, Jeffrey R. Gingrich, Vasileios J. Assikis, Anders Björk, Orjan Nordle, Goran Forsberg, Michael A. Carducci, and Andrew J. Armstrong. “Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.” J Clin Oncol 29, no. 30 (October 20, 2011): 4022–28. https://doi.org/10.1200/JCO.2011.35.6295.
    Full Text Link to Item
  - Antonarakis, E. S., and A. J. Armstrong. “Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer.” Prostate Cancer Prostatic Dis 14, no. 3 (September 2011): 192–205. https://doi.org/10.1038/pcan.2011.23.
    Full Text Link to Item
  - Antonarakis, E. S., and A. J. Armstrong. “Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer.” Prostate Cancer Prostatic Dis 14, no. 3 (September 2011): 206–18. https://doi.org/10.1038/pcan.2011.24.
    Full Text Link to Item
  - Sonpavde, Guru, Gregory R. Pond, William R. Berry, Ronald de Wit, Mario A. Eisenberger, Ian F. Tannock, and Andrew J. Armstrong. “The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.” Cancer 117, no. 17 (September 1, 2011): 3963–71. https://doi.org/10.1002/cncr.25982.
    Full Text Link to Item
  - Bitting, Rhonda L., John Madden, and Andrew J. Armstrong. “Therapy for non-clear cell histologies in renal cancer.” Curr Clin Pharmacol 6, no. 3 (August 2011): 169–80. https://doi.org/10.2174/157488411797189460.
    Full Text Link to Item
  - Armstrong, Andrew J., Matthew S. Marengo, Sebastian Oltean, Gabor Kemeny, Rhonda L. Bitting, James D. Turnbull, Christina I. Herold, Paul K. Marcom, Daniel J. George, and Mariano A. Garcia-Blanco. “Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers.” Mol Cancer Res 9, no. 8 (August 2011): 997–1007. https://doi.org/10.1158/1541-7786.MCR-10-0490.
    Full Text Link to Item
  - Fleming, M. T., G. R. Pond, A. J. Armstrong, B. A. Wood, M. Brookes, L. H. Leopold, V. B. Matveev, J. M. Burke, J. R. Caton, and G. Sonpavde. “Ability of serum alkaline phosphatase (ALP) changes to complement PSA changes and predict survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel and prednisone (DP).” J Clin Oncol 29, no. 15_suppl (May 20, 2011): e15019.
    Link to Item
  - Pond, G. R., A. J. Armstrong, B. A. Wood, M. Brookes, L. H. Leopold, W. R. Berry, R. De Wit, M. A. Eisenberger, I. Tannock, and G. Sonpavde. “Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC).” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 4582.
    Link to Item
  - Fleming, M. T., G. R. Pond, A. J. Armstrong, B. A. Wood, M. Brookes, L. H. Leopold, V. B. Matveev, J. M. Burke, J. R. Caton, and G. Sonpavde. “Ability of serum alkaline phosphatase (ALP) changes to complement PSA changes and predict survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel and prednisone (DP).” Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): e15019–e15019. https://doi.org/10.1200/jco.2011.29.15_suppl.e15019.
    Full Text
  - George, D. J., S. Halabi, A. J. Zurita, P. Creel, K. Mundy, J. D. Turnbull, S. E. Yenser Wood, et al. “Investigator-initiated pilot study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCF Prostate Cancer Clinical Trials Consortium.” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 4664.
    Link to Item
  - Pond, G. R., A. J. Armstrong, B. A. Wood, M. Brookes, L. H. Leopold, W. R. Berry, R. De Wit, M. A. Eisenberger, I. Tannock, and G. Sonpavde. “Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC).” Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): 4582–4582. https://doi.org/10.1200/jco.2011.29.15_suppl.4582.
    Full Text
  - Armstrong, A. J., M. Haggman, W. M. Stadler, J. R. Gingrich, V. J. Assikis, O. Nordle, G. Forsberg, M. A. Carducci, and R. Pili. “Phase II study of tasquinimod in chemotherapy-naive patients with metastatic castrate-resistant prostate cancer (CRPC): Safety and efficacy analysis including subgroups.” J Clin Oncol 29, no. 7_suppl (March 2011): 126.
    Link to Item
  - Armstrong, Andrew J., Stephen J. Freedland, and Mariano Garcia-Blanco. “Epithelial-mesenchymal transition in prostate cancer: providing new targets for therapy.” Asian J Androl 13, no. 2 (March 2011): 179–80. https://doi.org/10.1038/aja.2010.169.
    Full Text Link to Item
  - Pond, G. R., A. J. Armstrong, B. A. Wood, M. Brookes, L. H. Leopold, J. M. Burke, J. R. Caton, M. T. Fleming, and G. Sonpavde. “Assessment of two prognostic risk group methods to predict outcomes with docetaxel-based therapy in men with metastatic castration-resistant prostate cancer (mCRPC).” J Clin Oncol 29, no. 7_suppl (March 2011): 185.
    Link to Item
  - Sonpavde, G., G. R. Pond, W. R. Berry, R. De Wit, M. A. Eisenberger, I. Tannock, and A. J. Armstrong. “Association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.” J Clin Oncol 29, no. 7_suppl (March 2011): 118.
    Link to Item
  - Armstrong, A. J., M. Haggman, W. M. Stadler, J. R. Gingrich, V. J. Assikis, O. Nordle, G. Forsberg, M. A. Carducci, and R. Pili. “Phase II study of tasquinimod in chemotherapy-naive patients with metastatic castrate-resistant prostate cancer (CRPC): Safety and efficacy analysis including subgroups.” Journal of Clinical Oncology 29, no. 7_suppl (March 1, 2011): 126–126. https://doi.org/10.1200/jco.2011.29.7_suppl.126.
    Full Text
  - Pond, G. R., A. J. Armstrong, B. A. Wood, M. Brookes, L. H. Leopold, J. M. Burke, J. R. Caton, M. T. Fleming, and G. Sonpavde. “Assessment of two prognostic risk group methods to predict outcomes with docetaxel-based therapy in men with metastatic castration-resistant prostate cancer (mCRPC).” Journal of Clinical Oncology 29, no. 7_suppl (March 1, 2011): 185–185. https://doi.org/10.1200/jco.2011.29.7_suppl.185.
    Full Text
  - Sonpavde, G., G. R. Pond, W. R. Berry, R. De Wit, M. A. Eisenberger, I. Tannock, and A. J. Armstrong. “Association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.” Journal of Clinical Oncology 29, no. 7_suppl (March 1, 2011): 118–118. https://doi.org/10.1200/jco.2011.29.7_suppl.118.
    Full Text
  - Armstrong, A. J. “Radiotherapy aids survival in clinically staged, node+ prostate Ca: Commentary.” Oncology Report, no. JANUARY (January 1, 2011): 25.
  - Armstrong, A. J. “RT mode has an impact on pelvic fracture risk in older patients: Commentary.” Oncology Report, no. JANUARY (January 1, 2011): 25.
  - Bitting, Rhonda L., Andrew J. Armstrong, and Daniel J. George. “Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?” Clin Med Insights Oncol 5 (2011): 325–32. https://doi.org/10.4137/CMO.S5977.
    Full Text Link to Item
  - Armstrong, A. J. “Metastatic CRPC survival doesn't improve with added bevacizumab: Comment.” Oncology Report, no. JULY-AUGUST (July 1, 2010): 23.
  - Armstrong, A. J. “Denosumab prevents or stalls skeletal events in prostate cancer: Comment.” Oncology Report, no. JULY-AUGUST (July 1, 2010): 23.
  - Armstrong, A. J., and D. J. George. “Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.” Prostate Cancer Prostatic Dis 13, no. 2 (June 2010): 108–16. https://doi.org/10.1038/pcan.2009.62.
    Full Text Link to Item
  - Armstrong, Andrew J., George J. Netto, Michelle A. Rudek, Susan Halabi, David P. Wood, Patricia A. Creel, Kelly Mundy, et al. “A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.” Clin Cancer Res 16, no. 11 (June 1, 2010): 3057–66. https://doi.org/10.1158/1078-0432.CCR-10-0124.
    Full Text Link to Item
  - Armstrong, A. J. “Cabazitaxel prolongs survival in late metastatic CRPC: Commentary.” Oncology Report, no. MARCH-APRIL (May 20, 2010): 22.
  - Armstrong, A. J. “IMPACT update: Survival benefit of sipuleucel-T is durable: Commentary.” Oncology Report, no. MARCH-APRIL (May 20, 2010): 23.
  - Armstrong, A. J., D. J. George, and S. Halabi. “Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTor inhibition in patients with metastatic renal cell carcinoma (RCC).” Journal of Clinical Oncology 28, no. 15 (May 20, 2010).
    Link to Item
  - Pili, R., M. Haggman, W. M. Stadler, J. R. Gingrich, V. J. Assikis, A. Bjork, G. Forsberg, M. A. Carducci, and A. J. Armstrong. “A randomized, multicenter, international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer (CRPC).” Journal of Clinical Oncology 28, no. 15 (May 20, 2010).
    Link to Item
  - Turnbull, J. D., A. J. Armstrong, K. Morris, SE Yenser Wood, S. Voyles, Y. A. Fesko, and D. J. George. “A single arm phase Ib study of RAD001 and sunitinib in patients with advanced renal cell carcinoma (RCC).” Journal of Clinical Oncology 28, no. 15 (May 20, 2010).
    Link to Item
  - Armstrong, A. J., G. Kemeny, J. D. Turnbull, C. Chao, C. Winters, Y. A. Fesko, D. A. Bradley, S. Halabi, D. J. George, and M. Garcia-Blanco. “Impact of temsirolimus and anti-androgen therapy on circulating tumor cell (CTC) biology in men with castration-resistant metastatic prostate cancer (CRPC): A phase II study.” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): TPS249–TPS249. https://doi.org/10.1200/jco.2010.28.15_suppl.tps249.
    Full Text
  - Pond, G. R., G. Sonpavde, W. R. Berry, R. De Wit, A. J. Armstrong, M. A. Eisenberger, and I. Tannock. “Use of changes in serum alkaline phosphatase to predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy: A retrospective analysis of the TAX327 trial.” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 4637–4637. https://doi.org/10.1200/jco.2010.28.15_suppl.4637.
    Full Text
  - Sankhala, K. K., E. G. Chiorean, A. J. Armstrong, M. J. Borad, A. M. Traynor, S. M. Gadgeel, V. K. Langmuir, C. Eng, S. Kroll, and H. Burris. “Phase I/II study of TH-302 in combination with docetaxel in patients with solid tumors including NSCLC and castrate-resistant prostate cancer (CRPC).” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): e13527–e13527. https://doi.org/10.1200/jco.2010.28.15_suppl.e13527.
    Full Text
  - Armstrong, Andrew J., Ian F. Tannock, Ronald de Wit, Daniel J. George, Mario Eisenberger, and Susan Halabi. “The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.” Eur J Cancer 46, no. 3 (February 2010): 517–25. https://doi.org/10.1016/j.ejca.2009.11.007.
    Full Text Link to Item
  - Armstrong, Allison J., Abraham K. Gebre, John S. Parks, and Catherine C. Hedrick. “ATP-binding cassette transporter G1 negatively regulates thymocyte and peripheral lymphocyte proliferation.” J Immunol 184, no. 1 (January 1, 2010): 173–83. https://doi.org/10.4049/jimmunol.0902372.
    Full Text Link to Item
  - Armstrong, Andrew J., Elizabeth Garrett-Mayer, Ronald de Wit, Ian Tannock, and Mario Eisenberger. “Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer.” Clin Cancer Res 16, no. 1 (January 1, 2010): 203–11. https://doi.org/10.1158/1078-0432.CCR-09-2514.
    Full Text Link to Item
  - Armstrong, A. J. “TroVax vaccine delivers mixed results in renal cell carcinoma: Commentary.” Oncology Report, no. WINT (December 1, 2009): 26.
  - Armstrong, A. J. “Bevacizumab increases toxicity, VTE in bladder cancer: Commentary.” Oncology Report, no. FALL (September 1, 2009): 24.
  - Armstrong, A. J. “Second vaccine shows improved survival in prostate cancer: Commentary.” Oncology Report, no. FALL (September 1, 2009): 25.
  - Armstrong, Andrew J., and Phillip G. Febbo. “Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.” Oncologist 14, no. 8 (August 2009): 816–27. https://doi.org/10.1634/theoncologist.2009-0043.
    Full Text Link to Item
  - Araujo, J., A. J. Armstrong, E. L. Braud, E. Posadas, M. Lonberg, G. E. Gallick, G. C. Trudel, P. Paliwal, S. Agrawal, and C. J. Logothetis. “Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: A phase I/II study (CA180086).” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 5061.
    Link to Item
  - Armstrong, A. J., S. Halabi, I. F. Tannock, D. J. George, R. DeWit, and M. Eisenberger. “Development of risk groups in metastatic castration-resistant prostate cancer (mCRPC) to facilitate the identification of active chemotherapy regimens.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 5137.
    Link to Item
  - Armstrong, A. J., S. Halabi, R. de Wit, I. F. Tannock, and M. Eisenberger. “The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer.” Prostate Cancer Prostatic Dis 12, no. 1 (2009): 88–93. https://doi.org/10.1038/pcan.2008.36.
    Full Text Link to Item
  - Armstrong, Andrew J., Patricia Creel, James Turnbull, Cassandra Moore, Tracy A. Jaffe, Sherri Haley, William Petros, et al. “A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.” Clin Cancer Res 14, no. 19 (October 1, 2008): 6270–76. https://doi.org/10.1158/1078-0432.CCR-08-1085.
    Full Text Link to Item
  - Armstrong, A. J. “Abiraterone acetate active in castration-resistant trials: Commentary.” Oncology Report, no. FALL (September 1, 2008): 39.
  - Armstrong, A. J. “Thalidomide prolongs PFS following androgen failure: Commentary.” Oncology Report, no. FALL (September 1, 2008): 40.
  - Figlin, Robert A., Elizabeth Brown, Andrew J. Armstrong, Wallace Akerley, Al B. Benson, Harold J. Burstein, David S. Ettinger, et al. “NCCN Task Force Report: mTOR inhibition in solid tumors.” J Natl Compr Canc Netw 6 Suppl 5 (September 2008): S1-20.
    Link to Item
  - Whang, Y. E., C. N. Moore, A. J. Armstrong, W. K. Rathmell, P. A. Godley, J. M. Crane, G. I. Grigson, K. Morris, C. P. Watkins, and D. J. George. “A phase II trial of lapatinib in hormone refractory prostate cancer.” Journal of Clinical Oncology 26, no. 15 (May 20, 2008).
    Link to Item
  - Armstrong, A. J., S. Halabi, I. F. Tannock, D. Ronald, and M. A. Eisenberger. “The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 5074–5074. https://doi.org/10.1200/jco.2008.26.15_suppl.5074.
    Full Text
  - Armstrong, Andrew J., Elizabeth L. Garrett-Mayer, and Mario Eisenberger. “Re: Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.” J Natl Cancer Inst 100, no. 9 (May 7, 2008): 681–82. https://doi.org/10.1093/jnci/djn104.
    Full Text Link to Item
  - Ramiah, Veshana, Daniel J. George, and Andrew J. Armstrong. “Clinical endpoints for drug development in prostate cancer.” Curr Opin Urol 18, no. 3 (May 2008): 303–8. https://doi.org/10.1097/MOU.0b013e3282fb7807.
    Full Text Link to Item
  - Armstrong, Andrew J., and Daniel J. George. “New drug development in metastatic prostate cancer.” Urol Oncol 26, no. 4 (2008): 430–37. https://doi.org/10.1016/j.urolonc.2007.11.006.
    Full Text Link to Item
  - Chen, Franklin L., Andrew J. Armstrong, and Daniel J. George. “Cell signaling modifiers in prostate cancer.” Cancer J 14, no. 1 (2008): 40–45. https://doi.org/10.1097/PPO.0b013e318161d40f.
    Full Text Link to Item
  - Armstrong, A. J., E. Garrett-Mayer, M. Eisenberger, I. Tannock, and R. De Wit. “In reply [12].” Journal of Clinical Oncology 25, no. 35 (December 10, 2007): 5674. https://doi.org/10.1200/JCO.2007.14.5383.
    Full Text
  - Armstrong, Andrew J., Elizabeth S. Garrett-Mayer, Yi-Chun Ou Yang, Ronald de Wit, Ian F. Tannock, and Mario Eisenberger. “A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis.” Clin Cancer Res 13, no. 21 (November 1, 2007): 6396–6403. https://doi.org/10.1158/1078-0432.CCR-07-1036.
    Full Text Link to Item
  - Armstrong, Andrew J., and Daniel J. George. “Satraplatin in the treatment of hormone-refractory metastatic prostate cancer.” Ther Clin Risk Manag 3, no. 5 (October 2007): 877–83.
    Link to Item
  - Armstrong, Andrew J., Elizabeth Garrett-Mayer, Yi-Chun Ou Yang, Michael A. Carducci, Ian Tannock, Ronald de Wit, and Mario Eisenberger. “Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.” J Clin Oncol 25, no. 25 (September 1, 2007): 3965–70. https://doi.org/10.1200/JCO.2007.11.4769.
    Full Text Link to Item
  - Srinivasan, Ramaprasad, Andrew J. Armstrong, William Dahut, and Daniel J. George. “Anti-angiogenic therapy in renal cell cancer.” Bju Int 99, no. 5 Pt B (May 2007): 1296–1300. https://doi.org/10.1111/j.1464-410X.2007.06834.x.
    Full Text Link to Item
  - Armstrong, A. J., P. G. Febbo, D. J. George, and J. Moul. “Systemic strategies for prostate cancer.” Minerva Urol Nefrol 59, no. 1 (March 2007): 11–25.
    Link to Item
  - Mendiratta, Prateek, Andrew J. Armstrong, and Daniel J. George. “Current standard and investigational approaches to the management of hormone-refractory prostate cancer.” Rev Urol 9 Suppl 1, no. Suppl 1 (2007): S9–19.
    Link to Item
  - Armstrong, Andrew J., and Mario Eisenberger. “Does gonadotropin-releasing-hormone agonist therapy for prostate cancer increase the risk of fracture?” Nat Clin Pract Urol 3, no. 5 (May 2006): 246–47. https://doi.org/10.1038/ncpuro0462.
    Full Text Link to Item
  - Armstrong, Andrew J., and Michael A. Carducci. “New drugs in prostate cancer.” Curr Opin Urol 16, no. 3 (May 2006): 138–45. https://doi.org/10.1097/01.mou.0000193390.69845.bb.
    Full Text Link to Item
  - Armstrong, Andrew J., and Michael A. Carducci. “Advanced prostate cancer: the future.” Can J Urol 12 Suppl 2 (June 2005): 42–47.
    Link to Item
  - Armstrong, Andrew J., and Michael A. Carducci. “Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies.” Curr Oncol Rep 7, no. 3 (May 2005): 220–27. https://doi.org/10.1007/s11912-005-0077-y.
    Full Text Link to Item
  - Armstrong, Andrew J., and Michael A. Carducci. “Novel therapeutic approaches to advanced prostate cancer.” Clin Adv Hematol Oncol 3, no. 4 (April 2005): 271–82.
    Link to Item
  - Eck, S. L., and A. Armstrong. “EpCAM is an important suppressor of anti-tumor immunity [2].” Cancer Biology and Therapy 4, no. 4 (April 1, 2005).
  - Armstrong, Amy J., Brian T. McMahon, Steven L. West, and Allen Lewis. “Workplace discrimination and cumulative trauma disorders: the national EEOC ADA research project.” Work 25, no. 1 (2005): 49–56.
    Link to Item
  - Armstrong, Andrew, and Stephen L. Eck. “EpCAM: A new therapeutic target for an old cancer antigen.” Cancer Biol Ther 2, no. 4 (2003): 320–26. https://doi.org/10.4161/cbt.2.4.451.
    Full Text Link to Item
  - Nightingale, R. W., D. L. Camacho, A. J. Armstrong, J. J. Robinette, and B. S. Myers. “Inertial properties and loading rates affect buckling modes and injury mechanisms in the cervical spine.” J Biomech 33, no. 2 (February 2000): 191–97. https://doi.org/10.1016/s0021-9290(99)00156-6.
    Full Text Link to Item
  - Nightingale, R. W., A. J. Armstrong, D. L. Camacho, and B. S. Myers. “Cervical spine buckling: The effects of vertebral mass and loading rate.” American Society of Mechanical Engineers, Bioengineering Division (Publication) Bed 36 (1997): 231–32.
  - Fukasawa, K., R. Zhou, W. T. Matten, A. J. Armstrong, I. Daar, M. Oskarsson, B. K. Sathyanarayana, L. Maclvor, T. G. Wood, and G. F. Vande Woude. “Mutagenic analysis of functional domains of the mos proto-oncogene and identification of the sites important for MAPK activation and DNA binding.” Oncogene 11, no. 8 (October 19, 1995): 1447–57.
    Link to Item
  - Bevan, T. D., A. J. Manninen, J. B. Cook, A. J. Armstrong, J. R. Hook, and H. E. Hall. “Vortex Mutual Friction in Rotating Superfluid 3He-B.” Phys Rev Lett 74, no. 5 (January 30, 1995): 750–53. https://doi.org/10.1103/PhysRevLett.74.750.
    Full Text Link to Item
  - Mullins, T. R., V. V. Dmitriev, A. J. Armstrong, A. J. Manninen, J. R. Hook, and H. E. Hall. “Identification of the order parameter of 3He-A using low-field NMR measurements.” Phys Rev Lett 72, no. 26 (June 27, 1994): 4117–20. https://doi.org/10.1103/PhysRevLett.72.4117.
    Full Text Link to Item
  - Tang, Y., A. J. Armstrong, R. C. Mockler, and W. J. O’Sullivan. “Free-expansion melting of a colloidal monolayer.” Phys Rev Lett 62, no. 20 (May 15, 1989): 2401–4. https://doi.org/10.1103/PhysRevLett.62.2401.
    Full Text Link to Item
  - Bender, D. A., A. J. Armstrong, C. R. Monkhouse, and J. P. Richardson. “Changes in pancreatic tryptophan in the rat in response to fasting. The effect of B-cytotoxic agents and variation through the oestrous cycle.” Pflugers Arch 356, no. 3 (1975): 245–51. https://doi.org/10.1007/BF00583836.
    Full Text Link to Item
  - Ramalingam, sundhar, David Sermer, Rajan Gupta, Patrick Healy, Yuan Wu, Daniel George, Andrew Armstrong, and M. R. Harrison. “Changes in skeletal muscle cross sectional area (CSA) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZ).” Journal of Clinical Oncology 34 (n.d.). https://doi.org/10.1200/JCO.2016.34.15\_suppl.e16601.
    Full Text Link to Item
- Book Sections
  - Somarelli, J. A., A. J. Armstrong, M. U. Sheth, K. E. Ware, and M. K. Jolly. “Phenotypic plasticity and lineage switching in prostate cancer.” In Phenotypic Switching: Implications in Biology and Medicine, 591–615, 2020. https://doi.org/10.1016/B978-0-12-817996-3.00021-9.
    Full Text
  - Li, J., and A. J. Armstrong. “Prognostic and predictive biomarkers for castration resistant prostate cancer.” In Biomarkers in Disease: Methods, Discoveries and Applications: Biomarkers in Cancer, 447–80, 2015. https://doi.org/10.1007/978-94-007-7681-4_13.
    Full Text
  - Armstrong, A. J., and M. A. Carducci. “Chemotherapy for advanced prostate cancer.” In Treatment Methods for Early and Advanced Prostate Cancer, 327–39, 2008.
  - Armstrong, A. J., and M. A. Carducci. “Chemotherapy for advanced prostate cancer.” In Prostate Cancer: Principles and Practice, 989–1003, 2005.
- Other Articles
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Data from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” May 15, 2023. https://doi.org/10.1158/1078-0432.c.6516198.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” May 15, 2023. https://doi.org/10.1158/1078-0432.22820161.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” May 15, 2023. https://doi.org/10.1158/1078-0432.22820158.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” May 15, 2023. https://doi.org/10.1158/1078-0432.22820173.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” May 15, 2023. https://doi.org/10.1158/1078-0432.22820179.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” May 15, 2023. https://doi.org/10.1158/1078-0432.22820182.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” May 15, 2023. https://doi.org/10.1158/1078-0432.22820167.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” May 15, 2023. https://doi.org/10.1158/1078-0432.22820170.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” May 15, 2023. https://doi.org/10.1158/1078-0432.22820179.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” May 15, 2023. https://doi.org/10.1158/1078-0432.22820170.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” May 15, 2023. https://doi.org/10.1158/1078-0432.22820176.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” May 15, 2023. https://doi.org/10.1158/1078-0432.22820167.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” May 15, 2023. https://doi.org/10.1158/1078-0432.22820176.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” May 15, 2023. https://doi.org/10.1158/1078-0432.22820182.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” May 15, 2023. https://doi.org/10.1158/1078-0432.22820161.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” May 15, 2023. https://doi.org/10.1158/1078-0432.22820158.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Data from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” May 15, 2023. https://doi.org/10.1158/1078-0432.c.6516198.v4.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” May 15, 2023. https://doi.org/10.1158/1078-0432.22820173.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 12, 2023. https://doi.org/10.1158/1078-0432.22596015.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 12, 2023. https://doi.org/10.1158/1078-0432.22596021.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 12, 2023. https://doi.org/10.1158/1078-0432.22596027.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 12, 2023. https://doi.org/10.1158/1078-0432.22596024.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 12, 2023. https://doi.org/10.1158/1078-0432.22596024.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 12, 2023. https://doi.org/10.1158/1078-0432.22596018.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Data from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 12, 2023. https://doi.org/10.1158/1078-0432.c.6516198.v3.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 12, 2023. https://doi.org/10.1158/1078-0432.22596006.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 12, 2023. https://doi.org/10.1158/1078-0432.22596012.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 12, 2023. https://doi.org/10.1158/1078-0432.22596006.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 12, 2023. https://doi.org/10.1158/1078-0432.22596009.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 12, 2023. https://doi.org/10.1158/1078-0432.22596021.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 12, 2023. https://doi.org/10.1158/1078-0432.22596015.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 12, 2023. https://doi.org/10.1158/1078-0432.22596012.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 12, 2023. https://doi.org/10.1158/1078-0432.22596027.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 12, 2023. https://doi.org/10.1158/1078-0432.22596018.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 12, 2023. https://doi.org/10.1158/1078-0432.22596009.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 4, 2023. https://doi.org/10.1158/1078-0432.22553341.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 4, 2023. https://doi.org/10.1158/1078-0432.22553365.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 4, 2023. https://doi.org/10.1158/1078-0432.22553356.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 4, 2023. https://doi.org/10.1158/1078-0432.22553368.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 4, 2023. https://doi.org/10.1158/1078-0432.22553365.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 4, 2023. https://doi.org/10.1158/1078-0432.22553347.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 4, 2023. https://doi.org/10.1158/1078-0432.22553359.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 4, 2023. https://doi.org/10.1158/1078-0432.22553368.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 4, 2023. https://doi.org/10.1158/1078-0432.22553362.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 4, 2023. https://doi.org/10.1158/1078-0432.22553341.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 4, 2023. https://doi.org/10.1158/1078-0432.22553362.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 4, 2023. https://doi.org/10.1158/1078-0432.22553350.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 4, 2023. https://doi.org/10.1158/1078-0432.22553356.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 4, 2023. https://doi.org/10.1158/1078-0432.22553359.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 4, 2023. https://doi.org/10.1158/1078-0432.22553350.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Data from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 4, 2023. https://doi.org/10.1158/1078-0432.c.6516198.v2.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 4, 2023. https://doi.org/10.1158/1078-0432.22553347.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “Data from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer,” April 3, 2023. https://doi.org/10.1158/1541-7786.c.6545372.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “Figure S1 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer,” April 3, 2023. https://doi.org/10.1158/1541-7786.22527293.
    Full Text
  - Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “Figure S5 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer,” April 3, 2023. https://doi.org/10.1158/1541-7786.22527281.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “File S1 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer,” April 3, 2023. https://doi.org/10.1158/1541-7786.22527275.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “File S3 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer,” April 3, 2023. https://doi.org/10.1158/1541-7786.22527269.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “Figure S1 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer,” April 3, 2023. https://doi.org/10.1158/1541-7786.22527293.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “File S5 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer,” April 3, 2023. https://doi.org/10.1158/1541-7786.22527263.
    Full Text
  - Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “File S2 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer,” April 3, 2023. https://doi.org/10.1158/1541-7786.22527272.
    Full Text
  - Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “Supplementary Method from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer,” April 3, 2023. https://doi.org/10.1158/1541-7786.22527260.
    Full Text
  - Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “Figure S2 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer,” April 3, 2023. https://doi.org/10.1158/1541-7786.22527290.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “Figure S5 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer,” April 3, 2023. https://doi.org/10.1158/1541-7786.22527281.
    Full Text
  - Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “Table S1 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer,” April 3, 2023. https://doi.org/10.1158/1541-7786.22527257.
    Full Text
  - Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “Figure S3 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer,” April 3, 2023. https://doi.org/10.1158/1541-7786.22527287.
    Full Text
  - Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “File S4 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer,” April 3, 2023. https://doi.org/10.1158/1541-7786.22527266.
    Full Text
  - Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “Figure S2 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer,” April 3, 2023. https://doi.org/10.1158/1541-7786.22527290.
    Full Text
  - Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “Figure S3 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer,” April 3, 2023. https://doi.org/10.1158/1541-7786.22527287.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “Figure S6 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer,” April 3, 2023. https://doi.org/10.1158/1541-7786.22527278.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “File S5 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer,” April 3, 2023. https://doi.org/10.1158/1541-7786.22527263.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “Supplementary Method from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer,” April 3, 2023. https://doi.org/10.1158/1541-7786.22527260.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “File S4 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer,” April 3, 2023. https://doi.org/10.1158/1541-7786.22527266.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “File S1 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer,” April 3, 2023. https://doi.org/10.1158/1541-7786.22527275.
    Full Text
  - Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “Figure S6 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer,” April 3, 2023. https://doi.org/10.1158/1541-7786.22527278.
    Full Text
  - Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “File S3 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer,” April 3, 2023. https://doi.org/10.1158/1541-7786.22527269.
    Full Text
  - Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “Figure S4 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer,” April 3, 2023. https://doi.org/10.1158/1541-7786.22527284.
    Full Text
  - Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “Table S1 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer,” April 3, 2023. https://doi.org/10.1158/1541-7786.22527257.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “Figure S4 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer,” April 3, 2023. https://doi.org/10.1158/1541-7786.22527284.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “File S2 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer,” April 3, 2023. https://doi.org/10.1158/1541-7786.22527272.v1.
    Full Text
  - Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Supplementary Figure 3 from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma,” March 31, 2023. https://doi.org/10.1158/1078-0432.22478720.
    Full Text
  - Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Supplementary Figure 1 from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma,” March 31, 2023. https://doi.org/10.1158/1078-0432.22478726.v1.
    Full Text
  - Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Supplementary Figure 4a from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma,” March 31, 2023. https://doi.org/10.1158/1078-0432.22478714.v1.
    Full Text
  - Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Supplementary Figure 1 from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma,” March 31, 2023. https://doi.org/10.1158/1078-0432.22478726.
    Full Text
  - Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Supplementary Tables and Figures from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma,” March 31, 2023. https://doi.org/10.1158/1078-0432.22478711.
    Full Text
  - Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Supplementary Figure 4a from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma,” March 31, 2023. https://doi.org/10.1158/1078-0432.22478714.
    Full Text
  - Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Supplementary Figure 4B from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma,” March 31, 2023. https://doi.org/10.1158/1078-0432.22478717.v1.
    Full Text
  - Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Supplementary Figure 2 from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma,” March 31, 2023. https://doi.org/10.1158/1078-0432.22478723.
    Full Text
  - Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Supplementary Figure 3 from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma,” March 31, 2023. https://doi.org/10.1158/1078-0432.22478720.v1.
    Full Text
  - Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Supplementary Figure 4B from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma,” March 31, 2023. https://doi.org/10.1158/1078-0432.22478717.
    Full Text
  - Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Supplementary Figure 2 from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma,” March 31, 2023. https://doi.org/10.1158/1078-0432.22478723.v1.
    Full Text
  - Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Data from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma,” March 31, 2023. https://doi.org/10.1158/1078-0432.c.6530027.v1.
    Full Text
  - Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Data from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma,” March 31, 2023. https://doi.org/10.1158/1078-0432.c.6530027.
    Full Text
  - Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Supplementary Tables and Figures from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma,” March 31, 2023. https://doi.org/10.1158/1078-0432.22478711.v1.
    Full Text
  - Brown, Landon C., Susan Halabi, Joseph D. Schonhoft, Qian Yang, Jun Luo, David M. Nanus, Paraskevi Giannakakou, et al. “Supplementary Data from Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide,” March 31, 2023. https://doi.org/10.1158/1078-0432.22480589.
    Full Text
  - Brown, Landon C., Susan Halabi, Joseph D. Schonhoft, Qian Yang, Jun Luo, David M. Nanus, Paraskevi Giannakakou, et al. “Data from Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide,” March 31, 2023. https://doi.org/10.1158/1078-0432.c.6530474.v1.
    Full Text
  - Brown, Landon C., Susan Halabi, Joseph D. Schonhoft, Qian Yang, Jun Luo, David M. Nanus, Paraskevi Giannakakou, et al. “Supplementary Data from Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide,” March 31, 2023. https://doi.org/10.1158/1078-0432.22480589.v1.
    Full Text
  - Brown, Landon C., Susan Halabi, Joseph D. Schonhoft, Qian Yang, Jun Luo, David M. Nanus, Paraskevi Giannakakou, et al. “Data from Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide,” March 31, 2023. https://doi.org/10.1158/1078-0432.c.6530474.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” March 31, 2023. https://doi.org/10.1158/1078-0432.22438092.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” March 31, 2023. https://doi.org/10.1158/1078-0432.22438095.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” March 31, 2023. https://doi.org/10.1158/1078-0432.22438092.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” March 31, 2023. https://doi.org/10.1158/1078-0432.22438095.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” March 31, 2023. https://doi.org/10.1158/1078-0432.22438089.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” March 31, 2023. https://doi.org/10.1158/1078-0432.22438089.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” March 31, 2023. https://doi.org/10.1158/1078-0432.22438098.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” March 31, 2023. https://doi.org/10.1158/1078-0432.22438098.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Data from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” March 31, 2023. https://doi.org/10.1158/1078-0432.c.6516198.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” March 31, 2023. https://doi.org/10.1158/1078-0432.22438077.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” March 31, 2023. https://doi.org/10.1158/1078-0432.22438083.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” March 31, 2023. https://doi.org/10.1158/1078-0432.22438080.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” March 31, 2023. https://doi.org/10.1158/1078-0432.22438086.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” March 31, 2023. https://doi.org/10.1158/1078-0432.22438077.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” March 31, 2023. https://doi.org/10.1158/1078-0432.22438083.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” March 31, 2023. https://doi.org/10.1158/1078-0432.22438086.v1.
    Full Text
  - Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” March 31, 2023. https://doi.org/10.1158/1078-0432.22438080.v1.
    Full Text
  - Somarelli, Jason A., Daneen Schaeffer, Mathew S. Marengo, Tristan Bepler, Douglas Rouse, Anne F. Buckley, Jonathan I. Epstein, Andrew J. Armstrong, and Mariano A. Garcia-Blanco. “Abstract SS02-02: A long walk from FGFR2 alternative splicing to cancer progression.” Cancer Epidemiology, Biomarkers &Amp; Prevention. American Association for Cancer Research (AACR), November 1, 2014. https://doi.org/10.1158/1538-7755.disp13-ss02-02.
    Full Text
  - Armstrong, Andrew J., Judd W. Moul, and Daniel J. George. “What to order from the prostate cancer treatment menu?” Oncology (Williston Park), January 2012.
    Link to Item
  - Armstrong, Andrew J., Judd W. Moul, and Daniel J. George. “What to Order From the Prostate Cancer Treatment Menu? THE CRAWFORD/FLAIG ARTICLE REVIEWED.” Oncology New York. UBM MEDICA, January 1, 2012.
    Link to Item
- Conference Papers
  - Oya, M., A. J. Armstrong, A. Thiery-Vuillemin, N. Shore, G. Procopio, Ç. Arslan, N. Mehra, et al. “157O Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).” In Annals of Oncology, 33:S1495–S1495. Elsevier BV, 2022. https://doi.org/10.1016/j.annonc.2022.10.194.
    Full Text
  - Patierno, Brendon M., Wen-Chi Foo, Tyler Allen, Jason A. Somarelli, Kathryn E. Ware, Santosh Gupta, Sandra Wise, et al. “Characterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry.” In Prostate Cancer Prostatic Dis, 25:513–23, 2022. https://doi.org/10.1038/s41391-021-00460-y.
    Full Text Open Access Copy Link to Item
  - Zhang, T., M. Poellmann, S. -. J. Park, J. Bu, R. Zhao, Q. Zhou, A. Agarwal, et al. “1475P Association of circulating tumor cells (CTCs) with immune checkpoint inhibitor (ICI) responses in metastatic renal cell carcinoma (mRCC).” In Annals of Oncology, 33:S1221–S1221. Elsevier BV, 2022. https://doi.org/10.1016/j.annonc.2022.07.1578.
    Full Text
  - Armstrong, Andrew J., Taro Iguchi, Arun Azad, Russell Zelig Szmulewitz, Jeffrey Holzbeierlein, Arnauld Villers, Antonio Alcaraz, et al. “Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA) + androgen deprivation therapy (ADT) by high or low disease volume and progression to mHSPC (M0 at diagnosis) or de novo mHSPC (M1 at diagnosis): Post hoc analysis of the phase 3 ARCHES trial.” In Journal of Clinical Oncology, 40:115–115. American Society of Clinical Oncology (ASCO), 2022. https://doi.org/10.1200/jco.2022.40.6_suppl.115.
    Full Text
  - Chi, Kim N., Nabil Adra, Rohan Garje, Jeff M. Michalski, Jules Lavalaye, Mette Moe Kempel, Marcia Brackman, Kevin Perraud, Geoffrey Holder, and Andrew J. Armstrong. “Exposure-adjusted safety analyses of the VISION phase 3 trial of ¹⁷⁷Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.” In Journal of Clinical Oncology, 40:85–85. American Society of Clinical Oncology (ASCO), 2022. https://doi.org/10.1200/jco.2022.40.6_suppl.085.
    Full Text
  - Graham, Laura, Edward Green, Joseph J. Park, Olesia Kellezi, Clara Hwang, Pedro C. Barata, Mehmet Asim Bilen, et al. “DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes.” In Journal of Clinical Oncology, 40:129–129. American Society of Clinical Oncology (ASCO), 2022. https://doi.org/10.1200/jco.2022.40.6_suppl.129.
    Full Text
  - Paller, Channing Judith, Justin Lorentz, Tiffani DeMarco, Walter Michael Stadler, Andrew J. Armstrong, Mary-Ellen Taplin, Maha H. A. Hussain, et al. “PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.” In Journal of Clinical Oncology, 40:TPS191–TPS191. American Society of Clinical Oncology (ASCO), 2022. https://doi.org/10.1200/jco.2022.40.6_suppl.tps191.
    Full Text
  - Saad, Fred, Andrew J. Armstrong, Antoine Thiery-Vuillemin, Mototsugu Oya, Eugenia Loredo, Giuseppe Procopio, Juliana Janoski de Menezes, et al. “PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 40:11–11. American Society of Clinical Oncology (ASCO), 2022. https://doi.org/10.1200/jco.2022.40.6_suppl.011.
    Full Text
  - Spratt, Daniel Eidelberg, Yilun Sun, Douwe Van der Wal, Shih-Cheng Huang, Osama Mohamad, Andrew J. Armstrong, Jonathan David Tward, et al. “An AI-derived digital pathology-based biomarker to predict the benefit of androgen deprivation therapy in localized prostate cancer with validation in NRG/RTOG 9408.” In Journal of Clinical Oncology, 40:223–223. American Society of Clinical Oncology (ASCO), 2022. https://doi.org/10.1200/jco.2022.40.6_suppl.223.
    Full Text
  - Zengin, Zeynep Busra, Nicholas Henderson, Joseph J. Park, Alicia Ali, Clara Hwang, Pedro C. Barata, Mehmet Asim Bilen, et al. “Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts).” In Journal of Clinical Oncology, 40:138–138. American Society of Clinical Oncology (ASCO), 2022. https://doi.org/10.1200/jco.2022.40.6_suppl.138.
    Full Text
  - Zhang, Jiaren, Bob Zimmermann, Giuseppe Galletti, Susan Halabi, Ada Gjyrezi, Qian Yang, Santosh Gupta, et al. “Association of circulating tumor cell RB1 loss RNA signature with outcomes and immune phenotypes in men with mCRPC.” In Journal of Clinical Oncology, 40:139–139. American Society of Clinical Oncology (ASCO), 2022. https://doi.org/10.1200/jco.2022.40.6_suppl.139.
    Full Text
  - Armstrong, A. J., F. Saad, A. Thiery-Vuillemin, M. Oya, N. D. Shore, N. Mehra, M. Ozguroglu, et al. “Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial.” In Annals of Oncology, 33:S1168–S1168, 2022.
    Link to Item
  - Armstrong, A. J., O. Sartor, F. Saad, J. Czernin, N. D. Shore, A. T. Kendi, T. M. Beer, et al. “Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castrationresistant prostate cancer in the VISION trial.” In Annals of Oncology, 33:S1169–70, 2022.
    Link to Item
  - Armstrong, Andrew J., Nicolas Mottet, Taro Iguchi, Russell Zelig Szmulewitz, Jeffrey Holzbeierlein, Arnauld Villers, Antonio Alcaraz, et al. “Radiographic progression in the absence of prostate-specific antigen (PSA) progression in patients with metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analysis of ARCHES.” In Journal of Clinical Oncology, Vol. 40, 2022.
    Link to Item
  - Armstrong, Andrew J., Noel W. Clarke, Antoine Thiery-Vuillemin, Mototsugu Oya, Giuseppe Procopio, Juliana Janoski De Menezes, Gustavo Colagiovanni Girotto, et al. “Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial.” In Journal of Clinical Oncology, Vol. 40, 2022.
    Link to Item
  - Azad, Arun, Taro Iguchi, Boris Alekseev, Neal D. Shore, Jennifer Sugg, Gabriel P. Haas, Michele Wozniak, et al. “Prevalence of DNA damage repair (DDR) alterations in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving enzalutamide (ENZA) or placebo (PBO) plus androgen deprivation therapy (ADT): ARCHES post hoc analysis.” In Journal of Clinical Oncology, Vol. 40, 2022.
    Link to Item
  - Chen, Yu-Wei, Matthew D. Tucker, Landon Carter Brown, Hesham Abdallah Yasin, Kristin Kathleen Ancell, Andrew J. Armstrong, Katy Beckermann, et al. “Association between decline of neutrophil-to-eosinophil ratio (NER) at week 6 after ipilimumab plus nivolumab initiation and improved clinical outcomes in metastatic renal cell carcinoma (mRCC).” In Journal of Clinical Oncology, Vol. 40, 2022.
    Link to Item
  - Danila, Daniel Costin, David Michael Waterhouse, Leonard Joseph Appleman, David William Pook, Nobuaki Matsubara, Tanya B. Dorff, Jae-Lyun Lee, et al. “A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, Vol. 40, 2022.
    Link to Item
  - Gupta, S., Q. Yang, S. Halabi, A. Tubbs, Y. Gore, D. J. George, D. M. Nanus, et al. “The impact of PSMA-positive circulating tumor cells in men with metastatic castrate-resistant prostate cancer (mCRPC).” In Annals of Oncology, 33:S1165–66, 2022.
    Link to Item
  - Hwang, Clara, Nicholas Henderson, Frank Cameron Cackowski, Amanda Pilling, Albert Jang, Shoshana Rothstein, Matthew Labriola, et al. “Biomarker-directed therapy in black and white men with metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, Vol. 40, 2022.
    Link to Item
  - Kuo, Phillip, Jacob Hesterman, Kambiz Rahbar, Ayse T. Kendi, Xiao X. Wei, Bruno Fang, Nabil Adra, et al. “[Ga-68]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [Lu-177]Lu-PSMA-617 in patients with mCRPC: A VISION substudy.” In Journal of Clinical Oncology, Vol. 40, 2022.
    Link to Item
  - Morgans, Alicia K., Christopher Sweeney, Christopher J. D. Wallis, Susan Halabi, Andrew J. Armstrong, Frank Verholen, Jorge A. Ortiz, Anja Schmall, Shankar Srinivasan, and Marc-Oliver Grimm. “Progression patterns by types of metastatic spread, prostate-specific antigen (PSA), and clinical symptoms: Post-hoc analyses of ARAMIS.” In Journal of Clinical Oncology, Vol. 40, 2022.
    Link to Item
  - Petrylak, D. P., A. A. Azad, R. Z. Szmulewitz, T. Iguchi, N. D. Shore, J. Holzbeierlein, B. Alekseev, et al. “Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) who received prior androgen deprivation therapy (ADT) and reached low prostate-specific antigen (PSA) levels treated further with enzalutamide (ENZA): Post hoc analyses of ARCHES.” In Annals of Oncology, 33:S1183–84, 2022.
    Link to Item
  - Saad, F., A. J. Armstrong, A. Thiery-Vuillemin, M. Oya, N. D. Shore, G. Procopio, C. Arslan, et al. “Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).” In Annals of Oncology, 33:S1160–S1160, 2022.
    Link to Item
  - Sharifi, Nima, Arun Azad, Mona Patel, Jason W. D. Hearn, Michele Wozniak, Fabian Zohren, Jennifer Sugg, Gabriel P. Haas, Arnulf Stenzl, and Andrew J. Armstrong. “The association of germline HSD3B1 genotype with outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without enzalutamide (ENZA) [ARCHES].” In Journal of Clinical Oncology, Vol. 40, 2022.
    Link to Item
  - Stenzl, A., N. D. Shore, A. Villers, T. Iguchi, F. Gomez-Veiga, A. Alcaraz, B. Alekseev, et al. “Clinical outcomes of patients with metastatic Hormone-Sensitive Prostate Cancer (mHSPC) with Prostate-Specific Antigen (PSA) decline to undetectable levels on enzalutamide (ENZA): Post hoc analysis of ARCHES.” In European Urology, 81:S776–77, 2022.
    Link to Item
  - Szmulewitz, Russell Zelig, Jeffrey Holzbeierlein, Arun Azad, Taro Iguchi, Arnauld Villers, Antonio Alcaraz, Boris Alekseev, et al. “Clinical outcomes and safety of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) in patients aged < 75 and >= 75 years: ARCHES post hoc analysis.” In Journal of Clinical Oncology, Vol. 40, 2022.
    Link to Item
  - Tagawa, Scott T., Andrew J. Armstrong, Bernd J. Krause, Ken Herrmann, Kambiz Rahbar, Johann S. De Bono, Nabil Adra, et al. “Tolerability of [Lu-177]Lu-PSMA-617 by treatment exposure in patients with metastatic castration-resistant prostate cancer (mCRPC): A VISION study subgroup analysis.” In Journal of Clinical Oncology, Vol. 40, 2022.
    Link to Item
  - Thiery-Vuillemin, Antoine, Fred Saad, Andrew J. Armstrong, Mototsugu Oya, Karina Costa Maia Vianna, Mustafa Ozguroglu, Craig Gedye, et al. “Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial.” In Journal of Clinical Oncology, Vol. 40, 2022.
    Link to Item
  - Yu, Evan Y., Christopher Michael Pieczonka, Andrew J. Armstrong, Hiroyoshi Suzuki, James L. Bailen, Declan G. Murphy, Thierry Lebret, et al. “DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC).” In Journal of Clinical Oncology, 40:E17029–E17029, 2022.
    Link to Item
  - Zhang, Jiaren, Bob Zimmermann, Giuseppe Galletti, Susan Halabi, Ada Gjyrezi, Qian Yang, Santosh Gupta, et al. “Liquid biopsy transcriptomics identify pathways associated with poor outcomes and immune phenotypes in men with mCRPC.” In Cancer Research, Vol. 82, 2022.
    Link to Item
  - Koontz, B. F., K. E. Hoffman, T. Oyekunle, D. J. George, T. Zhang, W. R. Berry, W. R. Lee, et al. “Five Year Results of Short Course Complete Androgen Blockade With Abiraterone Acetate and LHRH Agonist for Unfavorable Intermediate and Favorable High Risk Prostate Cancer.” In International Journal of Radiation Oncology, Biology, Physics, 111:e281, 2021. https://doi.org/10.1016/j.ijrobp.2021.07.902.
    Full Text
  - Armstrong, A. J., T. Iguchi, A. A. Azad, R. Z. Szmulewitz, J. Holzbeierlein, A. Villers, A. Alcaraz, et al. “LBA25 Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC).” In Annals of Oncology, 32:S1300–1301. Elsevier BV, 2021. https://doi.org/10.1016/j.annonc.2021.08.2101.
    Full Text
  - Petrylak, D. P., J. L. Perez-Gracia, L. Lacombe, D. A. Bastos, H. Mahammedi, E. M. Kwan, S. Zschäbitz, et al. “579MO CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC).” In Annals of Oncology, 32:S629–30. Elsevier BV, 2021. https://doi.org/10.1016/j.annonc.2021.08.1092.
    Full Text
  - Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer.” In Mol Cancer Res, 19:1040–50, 2021. https://doi.org/10.1158/1541-7786.MCR-20-0975.
    Full Text Link to Item
  - Armstrong, Andrew J., Michael S. Gordon, Melissa Andrea Reimers, Alex Sedkov, Kate Lipford, Juliana Snavely-Merhaut, Sonia Kumar, Sylvie Mireille Guichard, and Neal Shore. “The Courage study: A first-in-human phase 1 study of the CBP/p300 inhibitor FT-7051 in men with metastatic castration-resistant prostate cancer.” In Journal of Clinical Oncology, 39:TPS5085–TPS5085. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.tps5085.
    Full Text
  - Armstrong, Andrew J., Taro Iguchi, Arun Azad, Arnauld Villers, Boris Alekseev, Daniel P. Petrylak, Russell Zelig Szmulewitz, et al. “The efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) on bone oligometastatic hormone-sensitive prostate cancer: A post hoc analysis of ARCHES.” In Journal of Clinical Oncology, 39:5071–5071. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.5071.
    Full Text
  - Tucker, Matthew D., Landon Carter Brown, Chester Kao, Nathan Hirshman, Emily Noelle Kinsey, Yu-Wei Chen, Kristin Kathleen Ancell, et al. “Association of baseline neutrophil-to-eosinophil ratio (NER) and neutrophil-to-lymphocyte ratio (NLR) with response to combination immunotherapy (IO) with ipilimumab plus nivolumab (ipi/nivo) in patients with metastatic renal cell carcinoma (mRCC).” In Journal of Clinical Oncology, 39:4563–4563. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.4563.
    Full Text
  - Armstrong, Andrew J., Neal D. Shore, Russell Z. Szmulewitz, Daniel P. Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Arun Azad, et al. “Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.” In J Urol, 205:1361–71, 2021. https://doi.org/10.1097/JU.0000000000001568.
    Full Text Link to Item
  - Brown, Landon Carter, Susan Halabi, Michael Sandon Humeniuk, Yuan Wu, Taofik Oyekunle, Jiaoti Huang, Monika Anand, et al. “Efficacy of the PD-L1 inhibitor avelumab in neuroendocrine or aggressive variant prostate cancer: Results from a phase II, single-arm study.” In Journal of Clinical Oncology, 39:89–89. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.89.
    Full Text
  - Fizazi, Karim, Pablo González Mella, Daniel Castellano, Jose Nicolas Minatta, Arash Rezazadeh, David R. Shaffer, Juan Carlos Vazquez Limon, et al. “CheckMate 9KD Arm B final analysis: Efficacy and safety of nivolumab plus docetaxel for chemotherapy-naïve metastatic castration-resistant prostate cancer.” In Journal of Clinical Oncology, 39:12–12. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.12.
    Full Text
  - Halabi, Susan, Qian Yang, Mark D. Starr, John C. Brady, Andrew J. Armstrong, Daniel J. George, William Kevin Kelly, Himisha Beltran, Michael J. Morris, and Andrew B. Nixon. “Identification of prognostic and predictive biomarkers of overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel, prednisone (DP) +/- bevacizumab (B) in CALGB 90401 (Alliance).” In Journal of Clinical Oncology, 39:154–154. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.154.
    Full Text
  - Harrison, Michael Roger, David Bartlett, Tian Zhang, Andrew J. Armstrong, Aubrie Coburn, Brian Coyne, Monika Anand, et al. “ASSET: Alternative schedule sunitinib in metastatic renal cell carcinoma (RCC)—Cardiopulmonary exercise testing (CPET).” In Journal of Clinical Oncology, 39:300–300. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.300.
    Full Text
  - Kelly, William Kevin, David William Pook, Leonard Joseph Appleman, David Michael Waterhouse, Lisa Horvath, William Jeffery Edenfield, Nobuaki Matsubara, et al. “Phase I study of AMG 509, a STEAP1 x CD3 T-cell recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 39:TPS183–TPS183. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.tps183.
    Full Text
  - Scher, Howard I., Andrew J. Armstrong, Joseph D. Schonhoft, Audrey Gill, Jimmy Zhao, Ethan Barnett, Emily Carbone, et al. “Development and validation of circulating tumor cell (Epic Sciences) enumeration as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.” In Journal of Clinical Oncology, 39:157–157. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.157.
    Full Text
  - Tucker, Matthew D., Andrew Lachlan Schmidt, Chih-Yuan Hsu, Yu Shyr, Andrew J. Armstrong, Ziad Bakouny, Christina Hunter Chapman, et al. “Severe-COVID-19 and mortality among patients (pts) with prostate cancer (PCa) receiving androgen deprivation therapy (ADT).” In Journal of Clinical Oncology, 39:39–39. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.39.
    Full Text
  - Zhang, Tian, Bridget F. Koontz, Scott T. Tagawa, Himanshu Nagar, Rhonda L. Bitting, Bart Frizzell, Luke T. Nordquist, et al. “Interim analysis of STARTAR: A phase II salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).” In Journal of Clinical Oncology, 39:90–90. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.90.
    Full Text
  - Shah, Anand, Thomas J. Polascik, Daniel J. George, John Anderson, Terry Hyslop, Alicia M. Ellis, Andrew J. Armstrong, et al. “Implementation and Impact of a Risk-Stratified Prostate Cancer Screening Algorithm as a Clinical Decision Support Tool in a Primary Care Network.” In J Gen Intern Med, 36:92–99, 2021. https://doi.org/10.1007/s11606-020-06124-2.
    Full Text Link to Item
  - Alcaraz, A., R. Z. Szmulewitz, N. Shore, E. D. Crawford, D. P. Petrylak, J. Holzbeierlein, A. Villers, et al. “635P ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of efficacy by baseline prostate-specific antigen (PSA) levels.” In Annals of Oncology, 31:S523–24. Elsevier BV, 2020. https://doi.org/10.1016/j.annonc.2020.08.894.
    Full Text
  - Tombal, B. F., S. J. Freedland, A. J. Armstrong, T. M. Beer, A. Stenzl, C. N. Sternberg, M. Hussain, et al. “665P Impact of enzalutamide on patient-reported fatigue in hormone-sensitive prostate cancer (HSPC) or castration-resistant prostate cancer (CRPC).” In Annals of Oncology, 31:S536–37. Elsevier BV, 2020. https://doi.org/10.1016/j.annonc.2020.08.924.
    Full Text
  - Patierno, Brendon M., Wayne Glover, Wen-Chi Foo, Jason A. Somarelli, Kathryn E. Ware, Lingfan Xu, Yanjing Li, et al. “Abstract A114: Characterization of a metastatic prostate cancer xenograft derived from a patient of African ancestry.” In Cancer Epidemiology, Biomarkers &Amp; Prevention, 29:A114–A114. American Association for Cancer Research (AACR), 2020. https://doi.org/10.1158/1538-7755.disp18-a114.
    Full Text
  - Sartor, Oliver, Andrew J. Armstrong, Chiledum Ahaghotu, David G. McLeod, Matthew R. Cooperberg, David F. Penson, Philip W. Kantoff, et al. “Abstract D084: Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC)—final PROCEED analysis.” In Cancer Epidemiology, Biomarkers &Amp; Prevention, 29:D084–D084. American Association for Cancer Research (AACR), 2020. https://doi.org/10.1158/1538-7755.disp19-d084.
    Full Text
  - Agarwal, Anika, Jennifer Modliszewski, Lauren Davey, Marco Reyes-Martinez, Daniella Runyambo, David Corcoran, Holly Dressman, et al. “Investigating the role of the gastrointestinal microbiome in response to immune checkpoint inhibitors (ICIs) among patients (pts) with metastatic renal cell carcinoma (mRCC).” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
    Link to Item
  - Armstrong, Andrew J., Jun Luo, Monika Anand, Emmanuel S. Antonarakis, David M. Nanus, Paraskevi Giannakakou, Russell Zelig Szmulewitz, et al. “AR-V7 and prediction of benefit with taxane therapy: Final analysis of PROPHECY.” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
    Link to Item
  - Brown, Landon Carter, Kunal Desai, Chester Kao, Emily Noelle Kinsey, Patrick Healy, Julie Kephart, Michael Roger Harrison, et al. “A multicenter retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) and brain metastasis treated with ipilimumab and nivolumab.” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
    Link to Item
  - Brown, Landon Carter, Susan Halabi, Joseph Schonhoft, Jun Luo, David M. Nanus, Paraskevi Giannakakou, Russell Zelig Szmulewitz, et al. “Association of circulating tumor cell chromosomal instability with worse outcomes in men with mCRPC treated with abiraterone or enzalutamide.” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
    Link to Item
  - Desai, Kunal, Landon Carter Brown, Wei Wei, Kimberly D. Allman, Allison Martin, Laura S. Wood, Shilpa Gupta, et al. “Multicenter retrospective analysis of patients with metastatic renal cell carcinoma (mRCC) and bone metastases treated with ipilimumab and nivolumab.” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
    Link to Item
  - Marshall, Catherine Handy, Jong Chul Park, Theodore L. DeWeese, Serina King, Michaella Afful, Julia Hurrelbrink, Charlotte Manogue, et al. “Randomized phase II study of sipuleucel-T (SipT) with or without radium-223 (Ra223) in men with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
    Link to Item
  - Ross, Ashley, Andrew J. Armstrong, Christopher M. Pieczonka, James L. Bailen, Ronald F. Tutrone, Matthew R. Cooperberg, Christian P. Pavlovich, et al. “A comparison of sipuleucel-T (sip-T) product parameters from two phase III studies: PROVENT in active surveillance prostate cancer and IMPACT in metastatic castrate-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
    Link to Item
  - Zhang, Tian, Julie Kephart, Elizabeth Bronson, Monika Anand, Christine Daly, Ivan Spasojevic, Hannah Berg, et al. “Disulfiram (DSF) pharmacokinetics (PK) and copper PET imaging in a phase Ib study of intravenous (IV) copper loading with oral DSF for patients with metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
    Link to Item
  - Zhang, Tian, Yuan Wu, Anika Agarwal, Mark D. Starr, Marco Reyes-Martinez, Monika Anand, Daniella Runyambo, et al. “Longitudinal multiplex cytokine analysis for patients (pts) with metastatic renalcell carcinoma (mRCC) treated with ipilimumab/nivolumab (I plus N).” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
    Link to Item
  - Kao, Chester, Eric Powers, Michael B. Datto, Michelle Green, Michael Roger Harrison, Andrew J. Armstrong, Daniel J. George, Jeffrey Melson Clarke, John H. Strickler, and Tian Zhang. “Tumor mutational burden (TMB) as a predictive biomarker of immune checkpoint blockade (ICB) in metastatic solid tumors.” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
    Link to Item
  - Brown, Landon Carter, Ramy Sedhom, Eric B. Schwartz, Jason Zhu, Chester Kao, Matthew D. Tucker, Matthew Labriola, et al. “Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types.” In Journal of Clinical Oncology, Vol. 38, 2020.
    Link to Item
  - Garmezy, Benjamin, Tian Zhang, Andrew Leonard Laccetti, Minas P. Economides, Amishi Yogesh Shah, Nizar M. Tannir, Eric Jonasch, et al. “Combination therapy with nivolumab and tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.” In Journal of Clinical Oncology, Vol. 38, 2020.
    Link to Item
  - Hong, Jun Hyuk, Arnulf Stenzl, Russell Z. Szmulewitz, Daniel Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Arun Azad, et al. “Arches - the role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (MHSPC): post hoc analyses of high and low disease volume and risk groups.” In International Journal of Urology, 27:102–3, 2020.
    Link to Item
  - Iguchi, Taro, Yeong-Shiau Pu, Go Kimura, Seok-Soo Byun, Hong Koo Ha, Jun Hyuk Hong, Jian-Ri Li, et al. “Post hoc analysis of East Asian subpopulation in arches, a phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (MHSPC).” In International Journal of Urology, 27:96–97, 2020.
    Link to Item
  - Kelly, W Kevin, Daniel Costin Danila, William Jeffery Edenfield, Rahul Raj Aggarwal, Daniel Peter Petrylak, A Oliver Sartor, Christopher Joseph Sumey, et al. “Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, Vol. 38, 2020.
    Link to Item
  - Marshall, Catherine Handy, Jong Chul Park, Wei Fu, Hao Wang, Theodore L. DeWeese, Serina King, Michaella Afful, et al. “Results of the randomized phase II study of sipuleucel-T (Sip-T) +/- Radium-223 (Ra-223) in men with bone-metastatic castration resistant prostate cancer.” In Journal of Clinical Oncology, Vol. 38, 2020.
    Link to Item
  - Morris, Michael J., Lawrence Fong, Daniel Peter Petrylak, A Oliver Sartor, Celestia S. Higano, Lance C. Pagliaro, Ajjai Shivaram Alva, et al. “Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial.” In Journal of Clinical Oncology, Vol. 38, 2020.
    Link to Item
  - Schweizer, Michael T., Gavin Ha, Roman Gulati, Landon C. Brown, Rana R. McKay, Tanya Dorff, Anna C. H. Hoge, et al. “CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade.” In Jco Precis Oncol, 4:382–92, 2020. https://doi.org/10.1200/po.19.00383.
    Full Text Link to Item
  - Shore, N. D., E. D. Crawford, R. Z. Szmulewitz, D. Petrylak, J. Holzbeierlein, A. Villers, A. Azad, et al. “Impact of baseline disease volume and prior docetaxel therapy on PSA-related outcomes in patients with mHSPC receiving enzalutamide plus ADT.” In Swiss Medical Weekly, 25S-26S, 2020.
    Link to Item
  - Watson, Catherine, Sarah Tait, Lindsay Soo, Jennifer Kay Plichta, Tian Zhang, Edgardo Castellar, Andrew J. Armstrong, et al. “The prevalence of germline mutations among patients with solid tumors with genomic alterations identified on tumor testing: Results from a tertiary care academic center molecular tumor board.” In Journal of Clinical Oncology, Vol. 38, 2020.
    Link to Item
  - Yu, Evan Y., Christopher Michael Pieczonka, Alberto Briganti, Declan G. Murphy, Thierry Lebret, Murilo Luz, Hiroyoshi Suzuki, et al. “DAROL: DARolutamide ObservationaL study patients in nonmetastatic castration-resistant prostate cancer (nmCRPC) patients.” In Journal of Clinical Oncology, Vol. 38, 2020.
    Link to Item
  - Fizazi, K., P. Gonzalez Mella, D. Castellano, N. Minatta, A Rezazadeh Kalebasty, D. Shaffer, J. C. Vazquez Limon, et al. “Efficacy and safety of nivolumab in combination with docetaxel in men with metastatic castration-resistant prostate cancer in CheckMate 9KD.” In Annals of Oncology, Vol. 30. OXFORD UNIV PRESS, 2019.
    Link to Item
  - Stenzl, A., R. Z. Szmulewitz, D. P. Petrylak, J. Holzbeierlein, A. Villers, A. A. Azad, A. Alcaraz, et al. “ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups.” In Annals of Oncology, 30:332-+. OXFORD UNIV PRESS, 2019.
    Link to Item
  - Tran, B., H. Kouros-Mehr, A. Fermin, L. Horvath, F. Roncolato, M. Rettig, T. Dorff, et al. “A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).” In Annals of Oncology, 30:353–353. OXFORD UNIV PRESS, 2019.
    Link to Item
  - Horvath, Lisa, Andrew J. Armstrong, Russell Szmulewitz, Daniel Petrylak, Arnauld Villers, Arun Azad, Antonio Alcaraz, et al. “Phase 3 Study of Androgen Deprivation Therapy (ADT) with Enzalutamide (ENZA) or Placebo (PBO) in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): The Arches Trial.” In Asia Pacific Journal of Clinical Oncology, 15:32–33. WILEY, 2019.
    Link to Item
  - Bueren, Moritz von, Andrew J. Armstrong, Russell Szmulewitz, Daniel Petrylak, Arnauld Villers, Arun Azad, Antonio Alcaraz, et al. “Androgen deprivation therapy with enzalutamide or placebo in metastatic hormone-sensitive prostate cancer: ARCHES.” In Swiss Medical Weekly, 149:16S-16S. E M H SWISS MEDICAL PUBLISHERS LTD, 2019.
    Link to Item
  - Armstrong, Andrew J., Russell Zelig Szmulewitz, Daniel Peter Petrylak, Jeffrey M. Holzbeierlein, Arnauld Villers, Arun Azad, Antonio Alcaraz, et al. “ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC).” In Journal of Clinical Oncology, 37:5048–5048. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.5048.
    Full Text
  - Autio, Karen A., Emmanuel S. Antonarakis, Raymond Baser, Mark N. Stein, Daniel H. Shevrin, Ulka N. Vaishampayan, Tina M. Mayer, et al. “Evaluation of the patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) with abiraterone acetate plus prednisone (AAP), degarelix (D), or the combination in men with biochemically recurrent prostate cancer (BCRPC).” In Journal of Clinical Oncology, 37:5080–5080. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.5080.
    Full Text
  - Chowdhury, Simon, Joaquin Mateo, Mitchell Gross, Andrew J. Armstrong, Marcia Cruz-Correa, Josep M. Piulats, Jean-Yves Blay, et al. “Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) and a circulating tumor cell (CTC) homologous recombination deficiency (HRD) phenotype or BRCA defects: A trial in progress.” In Journal of Clinical Oncology, 37:TPS5086–TPS5086. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.tps5086.
    Full Text
  - Halabi, Susan, Sandipan Dutta, John C. Araujo, Christopher Logothetis, Cora N. Sternberg, Andrew J. Armstrong, Michael Anthony Carducci, et al. “External validation of a prognostic model for overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 37:5022–5022. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.5022.
    Full Text
  - Labriola, Matthew, Jason Zhu, Sachica Cheris, Xin Liu, Kathryn Perkinson, Zuowei Su, Shannon McCall, et al. “Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC).” In Journal of Clinical Oncology, 37:e14259–e14259. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.e14259.
    Full Text
  - Mara, Alexandria, Jason Zhu, Yuan Wu, Tom Callis, Shan Yang, Edward D. Esplin, Robert L. Nussbaum, et al. “Prevalence of pathogenic germline variants in DNA repair by race, age, and ethnicity in men with prostate cancer.” In Journal of Clinical Oncology, 37:5062–5062. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.5062.
    Full Text
  - Morris, Michael J., Glenn Heller, Alan Haruo Bryce, Andrew J. Armstrong, Himisha Beltran, Olwen Mary Hahn, Eric C. McGary, et al. “Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 37:5008–5008. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.5008.
    Full Text
  - Sartor, A Oliver, Andrew J. Armstrong, Chiledum Ahaghotu, David G. McLeod, Matthew R. Cooperberg, David F. Penson, Philip W. Kantoff, et al. “Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PROCEED analysis.” In Journal of Clinical Oncology, 37:5035–5035. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.5035.
    Full Text
  - Stenzl, Arnulf, Curtis Dunshee, Ugo De Giorgi, Boris Alekseev, Taro Iguchi, Russell Zelig Szmulewitz, Thomas W. Flaig, et al. “Health-related quality of life (HRQoL) and pain progression with enzalutamide (ENZ) in metastatic hormone-sensitive prostate cancer (mHSPC) from the ARCHES study.” In Journal of Clinical Oncology, 37:5044–5044. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.5044.
    Full Text
  - Zhang, Tian, Bridget F. Koontz, Scott T. Tagawa, Himanshu Nagar, Rhonda L. Bitting, Bart Frizzell, Julia Rasmussen, et al. “A phase II Salvage Trial of AR Inhibition with ADT and Apalutamide with Radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (STARTAR).” In Journal of Clinical Oncology, 37:TPS5097–TPS5097. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.tps5097.
    Full Text
  - Zhu, Jason, Matthew D. Tucker, Chester Kao, Matthew Labriola, Sachica Cheris, Michael B. Datto, Yuan Wu, et al. “Immune checkpoint inhibitor response in tumors with LRP1B variants.” In Journal of Clinical Oncology, 37:e14291–e14291. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.e14291.
    Full Text
  - Armstrong, Andrew J., Carl A. Olsson, Ian D. Schnadig, Raoul S. Concepcion, Jeffrey L. Vacirca, Ronald F. Tutrone, Shaker R. Dakhil, et al. “Real-world PROCEED registry data: Sipuleucel-T in elderly men with metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 37:177–177. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.177.
    Full Text
  - Armstrong, Andrew J., Mohammed Al-Adhami, Ping Lin, Teresa Parli, Jennifer Sugg, Joyce Leta Steinberg, Bertrand F. TOMBAL, et al. “The clinical impact of bone scan (BS) flare with enzalutamide (ENZA) in men with metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 37:183–183. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.183.
    Full Text
  - Armstrong, Andrew J., Rhonda L. Bitting, Patrick Healy, Daniel J. George, Sung Kim, Tina M. Mayer, Carolyn Winters, et al. “Phase II trial enzalutamide and androgen deprivation therapy (ADT) with salvage radiation in men with high-risk PSA recurrent prostate cancer (PC): The STREAM trial.” In Journal of Clinical Oncology, 37:29–29. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.29.
    Full Text
  - Armstrong, Andrew J., Russell Zelig Szmulewitz, Daniel Peter Petrylak, Arnauld Villers, Arun Azad, Antonio Alcaraz, Boris Y. Alekseev, et al. “Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial.” In Journal of Clinical Oncology, 37:687–687. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.687.
    Full Text
  - Chowdhury, Simon, Joaquin Mateo, Mitchell Gross, Andrew J. Armstrong, Marcia Cruz-Correa, Josep M. Piulats, Jean-Yves Blay, et al. “A phase II trial in progress: Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer and a circulating tumor cell homologous recombination deficiency (HRD) phenotype or BRCA defects.” In Journal of Clinical Oncology, 37:TPS328–TPS328. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.tps328.
    Full Text
  - Clarke, Noel W., Andrew J. Armstrong, Antoine Thiery-Vuillemin, Mototsugu Oya, Dingwei Ye, Joaquin Mateo, Carsten Dietrich Goessl, Jinyu Kang, Sherry Liu, and Fred Saad. “PROPEL: A randomized, phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 37:TPS340–TPS340. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.tps340.
    Full Text
  - Harrison, Michael Roger, Michel Khouri, Andrew J. Armstrong, Tian Zhang, Megan Ann McNamara, Monika Anand, Ellen Bratt, et al. “PEAX: Men with metastatic castrate-resistant prostate cancer (mCRPC) treated with either sipuleucel-T (SIP-T), enzalutamide (ENZA) or abiraterone acetate (ABI) undergoing cardiopulmonary exercise testing (CPET).” In Journal of Clinical Oncology, 37:281–281. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.281.
    Full Text
  - TOMBAL, Bertrand F., Andrew J. Armstrong, Jeffrey Kent Barrus, Tomasz M. Beer, Simon Chowdhury, Christopher P. Evans, Axel Heidenreich, et al. “Adverse events of special interest assessed by review of safety data in enzalutamide castration-resistant prostate cancer (CRPC) trials.” In Journal of Clinical Oncology, 37:237–237. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.237.
    Full Text
  - Tucker, Matthew D., Jason Zhu, William R. Berry, Sundhar Ramalingam, Tian Zhang, Michael Roger Harrison, Yuan Wu, Patrick Healy, Daniel J. George, and Andrew J. Armstrong. “Pembrolizumab in men with heavily treated metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 37:172–172. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.172.
    Full Text
  - Vogelzang, Nicholas J., Philip W. Kantoff, Mark C. Scholz, Jeffrey L. Vacirca, Shaker R. Dakhil, Sanjay Goel, Matthew Harmon, Hong Tang, Bruce Brown, and Andrew J. Armstrong. “Experience with sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) with visceral spread from PROCEED.” In Journal of Clinical Oncology, 37:174–174. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.174.
    Full Text
  - Zhu, Jason, Matthew Labriola, Sachica Cheris, Xin Liu, Kathryn Perkinson, Zuowei Su, Shannon McCall, et al. “Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC).” In Journal of Clinical Oncology, 37:577–577. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.577.
    Full Text
  - Harrison, M. R., P. G. Davis, M. G. Khouri, R. T. Gupta, A. J. Armstrong, M. A. McNamara, T. Zhang, et al. “EXTEND: Safety and efficacy of exercise training in men receiving enzalutamide (ENZ) in combination with conventional androgen deprivation therapy (ADT) for hormone naïve prostate cancer (HSPC).” In Ann Oncol, 29 Suppl 8:viii623–24, 2018. https://doi.org/10.1093/annonc/mdy300.064.
    Full Text Link to Item
  - Zhang, Tian, SinJung Park, Daniella Runyambo, Michael J. Poellmann, Marco Reyes-Martinez, Zahra Mahbooba, Rebecca Green, et al. “Abstract 5702: Characterization of circulating tumor cells during immune checkpoint inhibition in metastatic renal cell carcinoma and malignant melanoma.” In Cancer Research, 78:5702–5702. American Association for Cancer Research (AACR), 2018. https://doi.org/10.1158/1538-7445.am2018-5702.
    Full Text
  - George, Daniel J., Elisabeth I. Heath, A Oliver Sartor, Guru Sonpavde, William R. Berry, Patrick Healy, Carolyn Winters, et al. “Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).” In Journal of Clinical Oncology, Vol. 36. AMER SOC CLINICAL ONCOLOGY, 2018.
    Link to Item
  - Armstrong, Andrew J., Santosh Gupta, Patrick Healy, Gabor Kemeny, Lauren Beth Leith, Michael Zalutsky, Charles Spritzer, et al. “Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223.” In Journal of Clinical Oncology, 36:5029–5029. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5029.
    Full Text
  - Armstrong, Andrew J., Susan Halabi, Jun Luo, David M. Nanus, Paraskevi Giannakakou, Russell Zelig Szmulewitz, Daniel Costin Danila, et al. “The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E).” In Journal of Clinical Oncology, 36:5004–5004. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5004.
    Full Text
  - Autio, Karen A., Emmanuel S. Antonarakis, Tina M. Mayer, Ulka N. Vaishampayan, Daniel H. Shevrin, Michael Roger Harrison, Scott T. Tagawa, et al. “Phase 2, randomized, 3-arm study of abiraterone acetate and prednisone (AAP), AAP plus degarelix (AAP+D), and degarelix (D) alone for patients (pts) with biochemically-recurrent prostate cancer (PC) following radical prostatectomy (RP).” In Journal of Clinical Oncology, 36:5016–5016. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5016.
    Full Text
  - Gupta, Santosh, Daniel H. Hovelson, Scott A. Tomlins, Gabor Kemeny, Chia-Jen Liu, Daniel J. George, Colin Rothwell, et al. “Analysis of genomic alterations in matched circulating tumor cell DNA (CTC DNA) and plasma tumor DNA (ctDNA) in men with metastatic castration resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 36:5065–5065. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5065.
    Full Text
  - Higano, Celestia S., Andrew J. Armstrong, A Oliver Sartor, Nicholas J. Vogelzang, Philip W. Kantoff, David G. McLeod, Christopher Michael Pieczonka, et al. “Cerebrovascular event (CVE) outcome and overall survival (OS) in patients (pts) treated with sipuleucel-T (sip-T) for metastatic castration-resistant prostate cancer (mCRPC): results from the PROCEED registry.” In Journal of Clinical Oncology, 36:e17018–e17018. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.e17018.
    Full Text
  - Sartor, A Oliver, Celestia S. Higano, Matthew R. Cooperberg, Nicholas J. Vogelzang, Shaker R. Dakhil, Christopher Michael Pieczonka, Jeff Vacirca, et al. “Sipuleucel-T (sip-T) overall survival (OS) and clinical outcomes by baseline (BL) prostate-specific antigen (PSA) quartiles in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROCEED registry.” In Journal of Clinical Oncology, 36:5041–5041. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5041.
    Full Text
  - Shantzer, Lindsey, Michala Ritz, Bennett B. Chin, Jorge Oldan, Aseem Anand, Taofik Oyekunle, Monika Anand, Andrew J. Armstrong, Daniel J. George, and Megan Ann McNamara. “Patterns of bone scan and pain response following treatment with Ra-223 in metastatic castrate resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 36:e17011–e17011. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.e17011.
    Full Text
  - Zhang, Tian, Rebecca Garland Austin, Sally E. Park, Daniella Runyambo, Rengasamy Boominathan, Chandra Rao, Elizabeth Bronson, et al. “Expression of immune checkpoints (ICs) on circulating tumor cells (CTCs) in men with metastatic prostate cancer (mPC).” In Journal of Clinical Oncology, 36:5059–5059. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5059.
    Full Text
  - Armstrong, Andrew J., Santosh Gupta, Patrick Healy, Gabor Kemeny, Lauren Beth Leith, Michael Zalutsky, Charles Spritzer, et al. “Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223.” In Journal of Clinical Oncology, 36:160–160. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.160.
    Full Text
  - Concepcion, Raoul, Andrew J. Armstrong, Lawrence Ivan Karsh, Stefan Holmstrom, Cristina Ivanescu, Curtis Dunshee, Neeraj Agarwal, et al. “Impact of enzalutamide (ENZA) vs. bicalutamide (BIC) on health-related quality of life (HRQoL) of patients (pts) with castration-resistant prostate cancer (CRPC): STRIVE study.” In Journal of Clinical Oncology, 36:234–234. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.234.
    Full Text
  - Freedland, Stephen J., Jenifer Allen, Andrew J. Armstrong, Judd W. Moul, Howard M. Sandler, Dana Levin, Lauren E. Howard, and Pao-hwa Lin. “Interim analysis of a prospective randomized trial of dietary carbohydrate restriction for men with a rising PSA after failed primary treatment: Carbohydrate and Prostate Study 2 (CAPS2).” In Journal of Clinical Oncology, 36:382–382. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.382.
    Full Text
  - Koontz, Bridget F., Karen E. Hoffman, Patrick Healy, Daniel J. George, Michael Roger Harrison, Tian Zhang, W Robert Lee, et al. “Phase II trial of 6 months ADT/abiraterone acetate plus prednisone (AAP) and definitive radiotherapy (AbiRT) for men with intermediate to high risk localized prostate cancer.” In Journal of Clinical Oncology, 36:11–11. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.11.
    Full Text
  - McNamara, Megan Ann, Michala Ritz, Bennett Chin, Jorge Oldan, Aseem Anand, Taofik Oyekunle, Monika Anand, Andrew J. Armstrong, and Daniel J. George. “Patterns of progression in bone and soft tissue following treatment with Ra-223 in metastatic castrate resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 36:222–222. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.222.
    Full Text
  - Sumanasuriya, Semini, Aurelius Gabriel Omlin, Andrew J. Armstrong, Gerhardt Attard, Kim N. Chi, Charlotte L. Bevan, David J. Waugh, et al. “Consensus statement on circulating biomarkers for advanced prostate cancer.” In Journal of Clinical Oncology, 36:299–299. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.299.
    Full Text
  - Zhang, Tian, Rebecca Garland Austin, Sally E. Park, Daniella Runyambo, Rengasamy Boominathan, Chandra Rao, Elizabeth Bronson, et al. “Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer (mPC).” In Journal of Clinical Oncology, 36:191–191. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.191.
    Full Text
  - Zhu, Jason, Matthew D. Tucker, Patrick Healy, Michael Sandon Humeniuk, Casey Jarvis, Daniel J. George, and Andrew J. Armstrong. “Clinical utility of Foundation One tissue molecular profiling in men with metastatic prostate cancer.” In Journal of Clinical Oncology, 36:318–318. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.318.
    Full Text
  - Armstrong, A. J., P. Lin, C. S. Higano, P. Iversen, C. N. Sternberg, B. Tombal, D. Phung, T. Parli, A. Krivoshik, and T. M. Beer. “Prognostic associations of prostate-specific antigen (PSA) decline with survival, radiographic response and progression in chemotherapy-naiive men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide.” In Annals of Oncology, Vol. 28. OXFORD UNIV PRESS, 2017.
    Link to Item
  - Armstrong, Andrew J., Susan Halabi, Patrick Healy, Joshi J. Alumkal, Carolyn Winters, Julie Kephart, Rhonda L. Bitting, et al. “Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.” In Eur J Cancer, 81:228–36, 2017. https://doi.org/10.1016/j.ejca.2017.02.030.
    Full Text Link to Item
  - Armstrong, A., C. Bui, K. Fitch, T Goss Sawhney, B. Brown, S. Flanders, M. Balk, J. Deangelis, and J. Chambers. “Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations.” In Curr Med Res Opin, 33:1133–39, 2017. https://doi.org/10.1080/03007995.2017.1308919.
    Full Text Link to Item
  - Armstrong, Andrew J., Lars Edenbrandt, Eva Bondesson, Aseem Anand, Orjan Nordle, Michael Anthony Carducci, and Michael J. Morris. “Phase 3 prognostic analysis of the automated bone scan index (aBSI) in men with bone-metastatic castration-resistant prostate cancer (CRPC).” In Journal of Clinical Oncology, 35:5006–5006. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.5006.
    Full Text
  - Humeniuk, Michael Sandon, Rajan T. Gupta, Megan Ann McNamara, Sundhar Ramalingam, Michael Roger Harrison, Daniel J. George, Yuan Wu, Patrick Healy, and Andrew J. Armstrong. “Association of neuroendocrine phenotype with platinum chemotherapy outcomes in men with metastatic prostate cancer.” In Journal of Clinical Oncology, 35:e16532–e16532. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.e16532.
    Full Text
  - Jaganathan, Hamsa, Anne Roc, Andrew J. Armstrong, Daniel J. George, and Wendy Turell. “The impact of continuing medical education (CME) programs in metastatic castration-resistant prostate cancer (CRPC).” In Journal of Clinical Oncology, 35:e18280–e18280. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.e18280.
    Full Text
  - Armstrong, Andrew J., Michael S. Humeniuk, Patrick Healy, Russell Szmulewitz, Carolyn Winters, Julie Kephart, Michael R. Harrison, et al. “Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.” In Prostate, 77:385–95, 2017. https://doi.org/10.1002/pros.23277.
    Full Text Link to Item
  - Beer, Tomasz M., Andrew J. Armstrong, Dana Rathkopf, Yohann Loriot, Cora N. Sternberg, Celestia S. Higano, Peter Iversen, et al. “Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.” In Eur Urol, 71:151–54, 2017. https://doi.org/10.1016/j.eururo.2016.07.032.
    Full Text Link to Item
  - Bryce, A. H., J. J. Alumkal, A. Armstrong, C. S. Higano, P. Iversen, C. N. Sternberg, D. E. Rathkopf, et al. “A post hoc analysis of radiographic progression with nonrising prostate-specific antigen in patients with metastatic castration-resistant prostate cancer (mCRPC) in the PREVAIL study.” In Annals of Oncology, 27:vi258, 2016. https://doi.org/10.1093/annonc/mdw372.44.
    Full Text
  - Sternberg, Cora, Andrew Armstrong, Roberto Pili, Siobhan Ng, Robert Huddart, Neeraj Agarwal, Denis Khvorostenko, et al. “Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.” In J Clin Oncol, 34:2636–43, 2016. https://doi.org/10.1200/JCO.2016.66.9697.
    Full Text Link to Item
  - Armstrong, Andrew J., Fred Saad, Neal D. Shore, Karim Fizazi, De Phung, Carl Dmuchowski, Mohammad Hirmand, David Forer, Howard I. Scher, and Johann S. De Bono. “Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM.” In Journal of Clinical Oncology, 34:5062–5062. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.5062.
    Full Text
  - Vogelzang, Nicholas J., Andrew J. Armstrong, Celestia S. Higano, A Oliver Sartor, Christopher Michael Pieczonka, Raoul S. Concepcion, Ronald F. Tutrone, et al. “Treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) in oncology (ONC) urology (URO) practices: Data from the PROCEED registry.” In Journal of Clinical Oncology, 34:e16503–e16503. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.e16503.
    Full Text
  - Armstrong, A. J., S. Halabi, P. Healy, W. R. Lee, B. F. Koontz, J. W. Moul, K. Mundy, et al. “A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.” In Prostate Cancer Prostatic Dis, 19:100–106, 2016. https://doi.org/10.1038/pcan.2015.59.
    Full Text Link to Item
  - Armstrong, Andrew J., Celestia S. Higano, A Oliver Sartor, Nicholas J. Vogelzang, William R. Berry, David F. Penson, Vahan Kassabian, et al. “Changing characteristics of patients treated with sipuleucel-T (sip-T) over time: Real-world experience from the PROCEED registry.” In Journal of Clinical Oncology, 34:320–320. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.320.
    Full Text
  - Armstrong, Andrew J., Fred Saad, Neal D. Shore, Karim Fizazi, De Phung, Carl Frank Dmuchowski, Mohammad Hirmand, David Forer, Howard I. Scher, and Johann S. De Bono. “Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM.” In Journal of Clinical Oncology, 34:266–266. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.266.
    Full Text
  - George, Daniel J., Susan Halabi, Patrick Healy, Sarah Gemberling, Carolyn Winters, Kelly Mundy, Michael Roger Harrison, Russell Zelig Szmulewitz, and Andrew J. Armstrong. “Phase Ib trial of docetaxel, prednisone, and pazopanib, in men with metastatic castration resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 34:275–275. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.275.
    Full Text
  - Higano, Celestia S., Andrew J. Armstrong, Matthew R. Cooperberg, Raoul S. Concepcion, Ronald F. Tutrone, Carl A. Olsson, Christopher Michael Pieczonka, et al. “Analysis of the PROCEED registry by baseline prostate-specific antigen (PSA) quartiles: Preliminary analysis of real-world sipuleucel-T (sip-T) use.” In Journal of Clinical Oncology, 34:193–193. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.193.
    Full Text
  - Morris, Michael J., Tomasz M. Beer, Yohann Loriot, Celestia S. Higano, Andrew J. Armstrong, Cora N. Sternberg, Johann S. De Bono, et al. “Correlation between radiographic progression-free survival (rPFS) and overall survival (OS): Results from PREVAIL.” In Journal of Clinical Oncology, 34:182–182. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.182.
    Full Text
  - Penson, David F., Andrew J. Armstrong, Raoul S. Concepcion, Kenneth Wu, Fong Wang, Andrew P. Krivoshik, De Phung, and Celestia S. Higano. “Sensitivity analyses for progression-free survival (PFS) and radiographic PFS (rPFS) from the phase II STRIVE trial comparing enzalutamide (ENZA) with bicalutamide (BIC) in men with castration-resistant prostate cancer (CRPC).” In Journal of Clinical Oncology, 34:169–169. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.169.
    Full Text
  - Sartor, A Oliver, Matthew R. Cooperberg, Andrew J. Armstrong, Nicholas J. Vogelzang, Jeffrey L. Vacirca, Mark C. Scholz, Shaker R. Dakhil, et al. “Real-world experience of therapeutic sequencing and time to first anticancer intervention (ACI) following sipuleucel-T (sip-T): Initial data from the PROCEED registry.” In Journal of Clinical Oncology, 34:194–194. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.194.
    Full Text
  - Sternberg, Cora N., Andrew J. Armstrong, Roberto Pili, Tore Nederman, and Michael Anthony Carducci. “A Phase 3, randomized, double-blind, placebo-controlled study of tasquinimod (TASQ) in men with metastatic castration-resistant prostate cancer (mCRPC), secondary endpoints.” In Journal of Clinical Oncology, 34:239–239. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.239.
    Full Text
  - Ware, Kathryn E., Daneen Schaeffer, Tian Zhang, Mariano A. Garcia-Blanco, and Andrew J. Armstrong. “Abstract 1847: AR-V7 regulation during epithelial plasticity.” In Cancer Research, 75:1847–1847. American Association for Cancer Research (AACR), 2015. https://doi.org/10.1158/1538-7445.am2015-1847.
    Full Text
  - Armstrong, Andrew J., Samuel Broderick, Tim Eisen, Walter Michael Stadler, Robert J. Jones, Jorge A. Garcia, Ulka N. Vaishampayan, et al. “Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN).” In Journal of Clinical Oncology, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.
    Link to Item
  - Zhang, Tian, Rengasamy Boominathan, Brad Foulk, Mark Carle Connelly, Chandra Rao, Gabor Kemeny, John H. Strickler, et al. “Evaluation of a novel c-MET based circulating tumor cell (CTC) biomarker in patients with gastrointestinal (GI) and genitourinary (GU) malignancies.” In Journal of Clinical Oncology, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.
    Link to Item
  - Higano, Celestia S., A Oliver Sartor, Nicholas J. Vogelzang, Shaker R. Dakhil, Raoul S. Concepcion, Christopher Michael Pieczonka, Jeffrey L. Vacirca, et al. “Administration of sipuleucel-T (sip-T) infusions (infs) outside of the clinical trial setting: Data from the PROCEED registry.” In Journal of Clinical Oncology, 33:e16027–e16027. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.e16027.
    Full Text
  - Li, Jing, Joshua Beaver, Rhonda Lynn Bitting, Simon Gregory, and Andrew J. Armstrong. “Genomic analysis of circulating tumor cells (CTCs) from men with metastatic castration resistant prostate cancer (mCRPC) in the context of enzalutamide therapy.” In Journal of Clinical Oncology, 33:5042–5042. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.5042.
    Full Text
  - Morris, Michael J., Patrick Hilden, Martin Edwin Gleave, Andrew J. Armstrong, Michael Anthony Carducci, Fred Saad, Erica Simone Dayan, et al. “Efficacy analysis of a phase III study of androgen deprivation therapy (ADT) +/- docetaxel (D) for men with biochemical relapse (BCR) after prostatectomy.” In Journal of Clinical Oncology, 33:5011–5011. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.5011.
    Full Text
  - Scher, Howard I., Michael J. Morris, Walter Michael Stadler, Celestia S. Higano, Susan Halabi, Matthew Raymond Smith, Ethan M. Basch, et al. “The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC).” In Journal of Clinical Oncology, 33:5000–5000. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.5000.
    Full Text
  - Graff, Julie Nicole, Giulia Baciarello, Andrew J. Armstrong, Celestia S. Higano, Peter Iversen, David Forer, Harry H. Mansbach, et al. “Clinical outcomes and safety in men ≥ 75 and < 75 years with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide in the phase 3 PREVAIL trial.” In Journal of Clinical Oncology, 33:200–200. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.7_suppl.200.
    Full Text
  - Tutrone, Ronald F., Chiledum Ahaghotu, Andrew J. Armstrong, Celestia S. Higano, Matthew R. Cooperberg, Laurence H. Belkoff, Carl A. Olsson, et al. “Characteristics of African Americans (AAs) treated with sipuleucel-T (sip-T): Comparison of clinical trial and real-world experience.” In Journal of Clinical Oncology, 33:272–272. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.7_suppl.272.
    Full Text
  - Zhang, Tian, Rengasamy Boominathan, Brad Foulk, Mark Carle Connelly, Chandra Rao, Gabor Kemeny, Herbert Hurwitz, Mariano A. Garcia-Blanco, and Andrew J. Armstrong. “Evaluation of a novel c-MET based circulating tumor cell (CTC) biomarker in patients with gastrointestinal malignancies.” In Journal of Clinical Oncology, 33:84–84. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.3_suppl.84.
    Full Text
  - Bhavsar, N. A., M. R. Harrison, L. J. Howie, A. J. Armstrong, K. Davis, Q. Chen, M. R. Pupa, A. Abernethy, D. J. George, and B. R. Hirsch. “1072PEXPERIENCE OF PATIENTS TREATED WITH SIPULEUCEL-T IN AN ACADEMIC SETTING.” In Ann Oncol, 25:iv369–70, 2014. https://doi.org/10.1093/annonc/mdu342.25.
    Full Text Link to Item
  - Furay, A., L. T. Nordquist, S. R. Dakhil, N. B. Green, E. I. Heath, R. F. Tutrone, N. J. Vogelzang, et al. “Impact of Prior Radiation Treatment on Sipuleucel-T Product Parameters in PROCEED Patients.” In International Journal of Radiation Oncology*Biology*Physics, 90:S407–8. Elsevier BV, 2014. https://doi.org/10.1016/j.ijrobp.2014.05.1296.
    Full Text
  - Armstrong, Andrew J., Bertrand Tombal, Cora N. Sternberg, Celestia S. Higano, Dana E. Rathkopf, Yohann Loriot, Fred Saad, et al. “Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 32:5007–5007. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.5007.
    Full Text
  - Halabi, Susan, William Kevin Kelly, Haojin Zhou, Andrew J. Armstrong, David Quinn, Karim Fizazi, Nicole C. Solomon, et al. “The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials.” In Journal of Clinical Oncology, 32:5002–5002. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.5002.
    Full Text
  - Li, Jing, Joshua Beaver, Rhonda Lynn Bitting, Simon Gregory, and Andrew J. Armstrong. “Genomic analysis of circulating tumor cells (CTCs) from men with metastatic castration resistant prostate cancer (mCRPC) in the context of enzalutamide therapy.” In Journal of Clinical Oncology, 32:e16059–e16059. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.e16059.
    Full Text
  - Morris, Michael J., Martin Edwin Gleave, Andrew J. Armstrong, Michael Anthony Carducci, Fred Saad, Kristine Peregrino Lacuna, and Howard I. Scher. “A randomized, open label, multicenter, phase 3, 2-arm study of androgen deprivation with leuprolide (L), ± docetaxel (D) for clinically asymptomatic prostate cancer (PC) subjects with a rising PSA following definitive local therapy: Safety results.” In Journal of Clinical Oncology, 32:5022–5022. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.5022.
    Full Text
  - Morris, Michael J., Yohann Loriot, Tomasz M. Beer, Celestia S. Higano, Andrew J. Armstrong, Cora N. Sternberg, Johann Sebastian De Bono, et al. “Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo.” In Journal of Clinical Oncology, 32:5054–5054. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.5054.
    Full Text
  - Zhang, Tian, Mallika S. Dhawan, Patrick Healy, Daniel J. George, Jorge Oldan, Bennett Chin, and Andrew J. Armstrong. “Clinical benefit of docetaxel or enzalutamide after progression on first-line abiraterone acetate and prednisone in men with metastatic castration resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 32:e16031–e16031. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.e16031.
    Full Text
  - Armstrong, Andrew J., Jing Li, Joshua Beaver, Rhonda Lynn Bitting, and Simon Gregory. “Genomic analysis of circulating tumor cells (CTCs) from men with metastatic castration resistant prostate cancer (mCRPC) in the context of enzalutamide therapy.” In Journal of Clinical Oncology, 32:65–65. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.4_suppl.65.
    Full Text
  - Armstrong, Andrew J., Rhonda Lynn Bitting, Gabor Kemeny, and Daniel J. George. “Evidence for circulating tumor cell (CTC) alkaline phosphatase (AP) expression in men with bone-metastatic castration-resistant prostate cancer (CRPC) during abiraterone acetate treatment.” In Journal of Clinical Oncology, 32:178–178. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.4_suppl.178.
    Full Text
  - Beer, Tomasz M., Andrew J. Armstrong, Cora N. Sternberg, Celestia S. Higano, Peter Iversen, Yohann Loriot, Dana E. Rathkopf, et al. “Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study.” In Journal of Clinical Oncology, 32:LBA1–LBA1. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.4_suppl.lba1.
    Full Text
  - Finkelstein, Steven E., Luke T. Nordquist, Shaker R. Dakhil, Nathan B. Green, Elisabeth I. Heath, Ronald Tutrone, Nicholas J. Vogelzang, et al. “Impact of prior radiation treatment (tx) on sipuleucel-T (sip-T) product parameters in PROCEED patients (pts).” In Journal of Clinical Oncology, 32:183–183. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.4_suppl.183.
    Full Text
  - Nabhan, Chadi, A Oliver Sartor, Matthew R. Cooperberg, Andrew J. Armstrong, Jeffrey L. Vacirca, Raoul S. Concepcion, William R. Berry, et al. “Sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) patients ≥80 years-old: Data from PROCEED.” In Journal of Clinical Oncology, 32:64–64. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.4_suppl.64.
    Full Text
  - Vogelzang, Nicholas J., Jeffrey L. Vacirca, Philip W. Kantoff, Mark C. Scholz, Shaker R. Dakhil, Luke T. Nordquist, Celestia S. Higano, et al. “Effect of prior abiraterone (ABI) or enzalutamide (ENZ) on sipuleucel-T (sip-T) manufacture in PROCEED patients (pts).” In Journal of Clinical Oncology, 32:185–185. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.4_suppl.185.
    Full Text
  - Armstrong, Andrew J., Reza Kaboteh, Michael Anthony Carducci, Jan-Erik Damber, Walter Michael Stadler, Hansen Mats, Lars Edenbrandt, et al. “Association of bone scan index (BSI) with prognostic biomarkers and survival in men with metastatic castration-resistant prostate cancer (mCRPC) enrolled in a prospective randomized controlled trial of tasquinimod.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Armstrong, Andrew J., Susan Halabi, Tim Eisen, Walter Michael Stadler, Robert R. Jones, Ultra N. Vaishampayan, Jorge A. Garcia, et al. “ASPEN: A randomized phase II trial of everolimus versus sunitinib in patients with metastatic non-clear cell renal cell carcinoma.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Bitting, Rhonda Lynn, Patrick Healy, Susan Halabi, Daniel J. George, Jung Hyun Ko, and Andrew J. Armstrong. “Evaluation of clinical phenotype, survival, and circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Halabi, Susan, Chen-Yen Lin, Eric Jay Small, Andrew J. Armstrong, Ellen B. Kaplan, Daniel Peter Petrylak, Cora N. Sternberg, et al. “A prognostic model for predicting overall survival in metastatic castrate-resistant prostate cancer (mCRPC) men treated with second-line chemotherapy.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Higano, Celestia S., Andrew J. Armstrong, Matthew R. Cooperberg, Philip W. Kantoff, James Bailen, Raoul S. Concepcion, Vahan Kassabian, et al. “Impact of prior docetaxel (D) on sipuleucel-T (sip-T) product parameters in PROCEED patients (pts).” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Halabi, Susan, Chen-Yen Lin, Eric Jay Small, Andrew J. Armstrong, Ellen B. Kaplan, Daniel Peter Petrylak, Cora N. Sternberg, et al. “A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013. https://doi.org/10.1200/jco.2013.31.6_suppl.24.
    Full Text Link to Item
  - Scher, Howard I., Karim Fizazi, Fred Saad, Kim N. Chi, Mary-Ellen Taplin, Cora N. Sternberg, Andrew J. Armstrong, Mohammad Hirmand, David Forer, and Johann Sebastian De Bono. “Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013. https://doi.org/10.1200/jco.2013.31.6_suppl.6.
    Full Text Link to Item
  - Schweizer, Michael Thomas, Aditya Bardia, Amanda L. Blackford, Jianqing Lin, Andrew J. Armstrong, Serina King, Michelle A. Rudek, Srinivasan Thomas Yegnasubramanian, and Michael Anthony Carducci. “A prostate cancer clinical trials consortium trial of disulfiram (D) in men with nonmetastatic recurrent prostate cancer (PCa).” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013. https://doi.org/10.1200/jco.2013.31.6_suppl.219.
    Full Text Link to Item
  - Armstrong, Andrew J., Tong Shen, Susan Halabi, Gabor Kemeny, Rhonda Lynn Bitting, Patricia Kartcheske, Elizabeth Embree, et al. “A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.” In Journal of Clinical Oncology, 31:105–105. American Society of Clinical Oncology (ASCO), 2013. https://doi.org/10.1200/jco.2013.31.6_suppl.105.
    Full Text
  - Corman, J., N. Dawson, S. Hall, C. Nabhan, A. Ferrari, A. J. Armstrong, M. I. Murdock, F. Stewart, N. Sheikh, and D. P. Petrylak. “OPENACT: PHASE 2, OPEN-LABEL STUDY OF SIPULEUCEL-T IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC).” In Annals of Oncology, 23:311–311. OXFORD UNIV PRESS, 2012.
    Link to Item
  - Scher, H. I., K. Fizazi, F. Saad, K. Chi, M. Taplin, C. N. Sternberg, A. J. Armstrong, M. Hirmand, B. Selby, and J. S. de Bono. “ASSOCIATION OF BASELINE CORTICOSTEROID WITH OUTCOMES IN A MULTIVARIATE ANALYSIS OF THE PHASE 3 AFFIRM STUDY OF ENZALUTAMIDE (ENZA), AN ANDROGEN RECEPTOR SIGNALING INHIBITOR (ARSI).” In Annals of Oncology, 23:297–297. OXFORD UNIV PRESS, 2012.
    Link to Item
  - Sonpavde, G., G. R. Pond, A. J. Armstrong, M. D. Galsky, B. A. Wood, S. Wang, J. Paolini, M. Lechuga, M. R. Smith, and M. D. Michaelson. “ASSOCIATION OF PROGRESSION BY PROSTATE CANCER WORKING GROUP (PCWG)-2 CRITERIA AND SURVIVAL IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER.” In Annals of Oncology, 23:297–98. OXFORD UNIV PRESS, 2012.
    Link to Item
  - Armstrong, Andrew J., Michael Haggman, Walter Michael Stadler, Jeffrey R. Gingrich, Vasily J. Assikis, Jonathan Polikoff, Samuel R. Denmeade, et al. “Tasquinimod and survival in men with metastatic castration-resistant prostate cancer: Results of long-term follow-up of a randomized phase II placebo-controlled trial.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - Bitting, Rhonda Lynn, Rengasamy Boominathan, Chandra Rao, Elizabeth Embree, Daniel J. George, Mark C. Connelly, Gabor Kemeny, Mariano Garcia-Blanco, and Andrew J. Armstrong. “Isolation of circulating tumor cells using a novel EMT-based capture method.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - De Bono, Johann Sebastian, Karim Fizazi, Fred Saad, Mary-Ellen Taplin, Cora N. Sternberg, Kurt Miller, Peter Mulders, et al. “Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - Halabi, Susan, Andrew J. Armstrong, A Oliver Sartor, Johann Sebastian De Bono, Ellen B. Kaplan, and Eric Jay Small. “Prostate-specific antigen decline (PSA) as a surrogate for overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) who failed first-line chemotherapy.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - George, D. J., S. Halabi, A. J. Zurita, P. Creel, K. Mundy, J. D. Turnbull, S. E. Yenser Wood, et al. “Investigator-initiated pilot study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCF Prostate Cancer Clinical Trials Consortium.” In Journal of Clinical Oncology, 29:4664–4664. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.4664.
    Full Text
  - Araujo, J., P. Mathew, A. J. Armstrong, E. L. Braud, E. Posadas, M. Lonberg, G. Gallick, G. C. Trudel, P. Paliwal, and C. J. Logothetis. “7028 Dasatinib and docetaxel combination treatment for patients with metastatic castration-resistant prostate cancer (CRPC): analysis of Study CA180–086.” In European Journal of Cancer Supplements, 7:415–415. Elsevier BV, 2009. https://doi.org/10.1016/s1359-6349(09)71406-5.
    Full Text
  - Araujo, J., A. J. Armstrong, E. L. Braud, E. Posadas, M. Lonberg, G. E. Gallick, G. C. Trudel, P. Paliwal, S. Agrawal, and C. J. Logothetis. “Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: A phase I/II study (CA180086).” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - Armstrong, A. J., S. Halabi, I. F. Tannock, D. J. George, R. Dewit, and M. Eisenberger. “Development of risk groups in metastatic castration-resistant prostate cancer (mCRPC) to facilitate the identification of active chemotherapy regimens.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - Armstrong, A. J. “Commentary.” In Oncology Report, 38, 2008.
  - Armstrong, A. J., M. A. Eisenberger, E. S. Garrett-Mayer, Y Ou Yang, M. A. Carducci, R. de Wit, and I. Tannock. “Analysis of prostate-specific antigen decline as a surrogate for overall survival in metastatic hormone-refractory prostate cancer (HRPC).” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.
    Link to Item
  - Eisenberger, M., E. S. Garrett-Mayer, Y Ou Yang, R. de Wit, I. Tannock, and A. J. Armstrong. “A multivariate prognostic nomogram incorporating PSA kinetics in hormone-refractory metastatic prostate cancer (HRPC).” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.
    Link to Item
  - Speca, J. C., A. L. Mears, P. A. Creel, S. E. Yenser, J. C. Bendell, M. A. Morse, H. I. Hurwitz, A. J. Armstrong, and D. J. George. “Phase I study of PTK787/ZK222584 (PTK/ZK) and RAD001 for patients with advanced solid tumors and dose expansion in renal cell carcinoma patients.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.
    Link to Item
  - Nightingale, R. W., A. J. Armstrong, D. L. Camacho, and B. S. Myers. “CERVICAL SPINE BUCKLING: THE EFFECTS OF VERTEBRAL MASS AND LOADING RATE.” In Asme International Mechanical Engineering Congress and Exposition, Proceedings (Imece), 1997-H:231–32, 1997. https://doi.org/10.1115/IMECE1997-0313.
    Full Text
Teaching & Mentoring
Recent Courses

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Previous Appointments & Affiliations

In the News

Global Scholarship

Research

Teaching

Selected Grants

External Relationships

Selected Publications

Academic Articles

Book Sections

Other Articles

Conference Papers

Recent Courses